<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">62174</article-id><article-id pub-id-type="doi">10.7554/eLife.62174</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>Iron derived from autophagy-mediated ferritin degradation induces cardiomyocyte death and heart failure in mice</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-203117"><name><surname>Ito</surname><given-names>Jumpei</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5149-9962</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-203118"><name><surname>Omiya</surname><given-names>Shigemiki</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-203119"><name><surname>Rusu</surname><given-names>Mara-Camelia</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-8369-3580</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-220065"><name><surname>Ueda</surname><given-names>Hiromichi</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-203120"><name><surname>Murakawa</surname><given-names>Tomokazu</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-203121"><name><surname>Tanada</surname><given-names>Yohei</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-203364"><name><surname>Abe</surname><given-names>Hajime</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-220066"><name><surname>Nakahara</surname><given-names>Kazuki</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-220067"><name><surname>Asahi</surname><given-names>Michio</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-203123"><name><surname>Taneike</surname><given-names>Manabu</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-203124"><name><surname>Nishida</surname><given-names>Kazuhiko</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-40738"><name><surname>Shah</surname><given-names>Ajay M</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6547-0631</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-59327"><name><surname>Otsu</surname><given-names>Kinya</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9697-0711</contrib-id><email>kinya.otsu@kcl.ac.uk</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>The School of Cardiovascular Medicine and Sciences, King’s College London British Heart Foundation Centre of Excellence</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff2"><label>2</label><institution>Department of Pharmacology, Faculty of Medicine, Osaka Medical College</institution><addr-line><named-content content-type="city">Osaka</named-content></addr-line><country>Japan</country></aff><aff id="aff3"><label>3</label><institution>Department of Cardiovascular Medicine, Graduate School of Medicine, Osaka University</institution><addr-line><named-content content-type="city">Osaka</named-content></addr-line><country>Japan</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Emoto</surname><given-names>Noriaki</given-names></name><role>Reviewing Editor</role><aff><institution>Kobe Pharmaceutical University</institution><country>Japan</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Barton</surname><given-names>Matthias</given-names></name><role>Senior Editor</role><aff><institution>University of Zurich</institution><country>Switzerland</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>02</day><month>02</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e62174</elocation-id><history><date date-type="received" iso-8601-date="2020-08-16"><day>16</day><month>08</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2021-01-08"><day>08</day><month>01</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Ito et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Ito et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-62174-v1.pdf"/><abstract><p>Heart failure is a major public health problem, and abnormal iron metabolism is common in patients with heart failure. Although iron is necessary for metabolic homeostasis, it induces a programmed necrosis. Iron release from ferritin storage is through nuclear receptor coactivator 4 (NCOA4)-mediated autophagic degradation, known as ferritinophagy. However, the role of ferritinophagy in the stressed heart remains unclear. Deletion of <italic>Ncoa4</italic> in mouse hearts reduced left ventricular chamber size and improved cardiac function along with the attenuation of the upregulation of ferritinophagy-mediated ferritin degradation 4 weeks after pressure overload. Free ferrous iron overload and increased lipid peroxidation were suppressed in NCOA4-deficient hearts. A potent inhibitor of lipid peroxidation, ferrostatin-1, significantly mitigated the development of pressure overload-induced dilated cardiomyopathy in wild-type mice. Thus, the activation of ferritinophagy results in the development of heart failure, whereas inhibition of this process protects the heart against hemodynamic stress.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>autophagy</kwd><kwd>iron</kwd><kwd>necrosis</kwd><kwd>ferritin</kwd><kwd>heart failure</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000274</institution-id><institution>British Heart Foundation</institution></institution-wrap></funding-source><award-id>CH/11/3/29051</award-id><principal-award-recipient><name><surname>Otsu</surname><given-names>Kinya</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000274</institution-id><institution>British Heart Foundation</institution></institution-wrap></funding-source><award-id>RG/16/15/32294</award-id><principal-award-recipient><name><surname>Otsu</surname><given-names>Kinya</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001674</institution-id><institution>Fondation Leducq</institution></institution-wrap></funding-source><award-id>RA15CVD04</award-id><principal-award-recipient><name><surname>Otsu</surname><given-names>Kinya</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010663</institution-id><institution>H2020 European Research Council</institution></institution-wrap></funding-source><award-id>692659</award-id><principal-award-recipient><name><surname>Otsu</surname><given-names>Kinya</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001691</institution-id><institution>Japan Society for the Promotion of Science</institution></institution-wrap></funding-source><award-id>18H02807</award-id><principal-award-recipient><name><surname>Otsu</surname><given-names>Kinya</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004206</institution-id><institution>Osaka University</institution></institution-wrap></funding-source><award-id>International Joint Research Promotion Program</award-id><principal-award-recipient><name><surname>Otsu</surname><given-names>Kinya</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000274</institution-id><institution>British Heart Foundation</institution></institution-wrap></funding-source><award-id>CH/1999001/11735</award-id><principal-award-recipient><name><surname>Shah</surname><given-names>Ajay M</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000274</institution-id><institution>British Heart Foundation</institution></institution-wrap></funding-source><award-id>RE/13/2/30182</award-id><principal-award-recipient><name><surname>Shah</surname><given-names>Ajay M</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Iron derived from autophagy-mediated ferritin degradation in response to pressure overload induces lipid peroxidation, necrotic cardiomyocyte death, and heart failure in mice.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Heart failure is the leading cause of death in developed countries (<xref ref-type="bibr" rid="bib31">Ponikowski et al., 2016</xref>). There is substantial evidence to suggest the involvement of oxidative stress and cardiomyocyte death in the pathogenesis of heart failure (<xref ref-type="bibr" rid="bib37">Whelan et al., 2010</xref>). Iron metabolism in heart failure patients is dysregulated (<xref ref-type="bibr" rid="bib18">Lavoie, 2020</xref>), but it remains unclear whether these changes are pathogenetic and detrimental or adaptative and protective for the heart. While iron is essential for oxidative phosphorylation, metabolite synthesis, and oxygen transport (<xref ref-type="bibr" rid="bib2">Andrews and Schmidt, 2007</xref>), it can generate toxic reactive hydroxyl radicals through the Fenton reaction (<xref ref-type="bibr" rid="bib30">Papanikolaou and Pantopoulos, 2005</xref>). Iron-dependent necrotic cell death is characterized by iron overload and an increased level of lipid reactive oxygen species (ROS) such as lipid hydroperoxides, leading to phospholipid damage, plasma membrane disruption, and caspase- and necrosome-independent cell death (<xref ref-type="bibr" rid="bib7">Dixon et al., 2012</xref>). Ferroptosis is a form of iron-dependent necrosis. Multiple molecular components contribute to the execution of ferroptosis, such as transferrin–iron, cystine–glutathione, and glutamine pathways (<xref ref-type="bibr" rid="bib13">Gao et al., 2015</xref>). Glutathione peroxidase 4 (GPX4) is a phospholipid hydroperoxide-reducing enzyme that uses glutathione as a substrate. The failure of GPX4 to clear lipid ROS leads to lipid peroxidation and ferroptosis (<xref ref-type="bibr" rid="bib38">Yang et al., 2014</xref>). Glutamate through the glutamine-fueled intracellular metabolic process glutaminolysis induces ferroptosis (<xref ref-type="bibr" rid="bib13">Gao et al., 2015</xref>). Ferroptosis has been implicated in the pathological process associated with ROS-induced tissue injury, such as ischemia/reperfusion in the brain, kidney, and heart (<xref ref-type="bibr" rid="bib9">Fang et al., 2019</xref>; <xref ref-type="bibr" rid="bib20">Linkermann et al., 2014</xref>; <xref ref-type="bibr" rid="bib36">Tuo et al., 2017</xref>).</p><p>Iron is stored in ferritin protein complexes in the cell to prevent an increase in the size of the labile iron pool that normally follows iron overload. Ferritin is a ubiquitously expressed cytosolic heteropolymer composed of H-chains (FTH1) and L-chains (FTL) (<xref ref-type="bibr" rid="bib4">Arosio et al., 2009</xref>). FTH1 has ferroxidase activity and sequestrates ferrous iron (Fe<sup>2</sup> ) from the Fenton reaction in which the spontaneous oxidation to ferric iron (Fe<sup>3</sup> ) donates single electrons to transform innocuous hydrogen peroxide to highly toxic hydroxyl free radicals. In the case of iron overload, ferritin subunits are induced by inactivating the iron regulatory protein (IREB)/iron-responsive element pathway. By contrast, under conditions of iron deficiency or increased iron requirement, ferritin is degraded and mediated through a selective form of autophagy, called ferritinophagy. Nuclear receptor coactivator 4 (NCOA4) is a cargo receptor for ferritinophagy that interacts with FTH1 and promotes the transport of ferritin to the autophagosome for degradation (<xref ref-type="bibr" rid="bib8">Dowdle et al., 2014</xref>; <xref ref-type="bibr" rid="bib21">Mancias et al., 2014</xref>). NCOA4-dependent iron release from ferritin storage is necessary for erythropoiesis (<xref ref-type="bibr" rid="bib6">Bellelli et al., 2016</xref>).</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Generation and characterization of cardiomyocyte-specific NCOA4-deficient mice</title><p>To examine the in vivo role of NCOA4-dependent ferritin degradation in the heart, cardiomyocyte-specific NCOA4-deficient mice were generated (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A and B</xref>). The homozygous floxed <italic>Ncoa4</italic> mice (<italic>Ncoa4</italic><sup>flox/flox</sup>) appeared normal and were externally indistinguishable from littermates of other genotypes. The <italic>Ncoa4</italic><sup>flox/flox</sup> mice were crossed with transgenic mice expressing α-myosin heavy chain (<italic>Myh6</italic>) promoter-driven Cre recombinase (Myh6-Cre) (<xref ref-type="bibr" rid="bib25">Nishida et al., 2004</xref>) to generate cardiomyocyte-specific NCOA4-deficient mice (<italic>Ncoa4</italic><sup>–/–</sup>), <italic>Ncoa4</italic><sup>flox/flox</sup>;Myh6-Cre<sup>+</sup>. The <italic>Ncoa4</italic><sup>flox/flox</sup>;Myh6-Cre<sup>–</sup> littermates were used as controls (<italic>Ncoa4<sup>+</sup></italic><sup>/+</sup>). The <italic>Ncoa4</italic><sup>+/+</sup> and <italic>Ncoa4</italic><sup>–/–</sup> mice were born at the expected Mendelian ratio (54 and 51 mice, respectively), and they grew to adulthood and were fertile. The protein and mRNA levels of NCOA4 were significantly decreased in <italic>Ncoa4</italic><sup>–/–</sup> hearts by 84% and 81% compared to control, respectively (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C and D</xref>). No differences in any physiological or echocardiographic parameters were observed between the <italic>Ncoa4</italic><sup>–/–</sup> and <italic>Ncoa4</italic><sup>+/+</sup> mice (<xref ref-type="supplementary-material" rid="fig1sdata2">Figure 1—source data 2</xref>).</p></sec><sec id="s2-2"><title>Attenuation of pressure overload-induced cardiac remodeling in NCOA4-deficient mice</title><p>To examine whether NCOA4 is related to cardiac remodeling in vivo, <italic>Ncoa4</italic><sup>+/+</sup> and <italic>Ncoa4</italic><sup>–/–</sup> mice were subjected to pressure overload employing transverse aortic constriction (TAC) and evaluated 4 weeks after the operation. Pressure overload increased the left ventricular (LV) chamber size, indicated by the end-diastolic and end-systolic LV internal dimensions, and reduced fractional shortening (an index of contractility) in <italic>Ncoa4</italic><sup>+/+</sup> mice compared to sham-operated controls (<xref ref-type="fig" rid="fig1">Figure 1A and B</xref>). These pressure overload-induced changes in heart size and function were suppressed in <italic>Ncoa4</italic><sup>–/–</sup> mice. The calculated LV mass, LV weight-to-tibia length ratio, and the cross-sectional area of cardiomyocytes, which are parameters for cardiac hypertrophy, were elevated by pressure overload in both <italic>Ncoa4</italic><sup>+/+</sup> and <italic>Ncoa4</italic><sup>–/–</sup> mice, but those were significantly lower in TAC-operated <italic>Ncoa4</italic><sup>–/–</sup> mice than in TAC-operated controls (<xref ref-type="fig" rid="fig1">Figure 1B,C and D</xref>). TAC-operated <italic>Ncoa4</italic><sup>+/+</sup> mice displayed higher mRNA expression levels of the cardiac remodeling markers, <italic>Nppa</italic>, <italic>Nppb</italic>, and <italic>Myh7</italic> than TAC-operated <italic>Ncoa4</italic><sup>–/–</sup> mice (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). Furthermore, the lung weight-to-tibia length ratio, an index of lung congestion, was significantly elevated in TAC-operated <italic>Ncoa4</italic><sup>+/+</sup> mice compared to both sham-operated <italic>Ncoa4</italic><sup>+/+</sup> and TAC-operated <italic>Ncoa4</italic><sup>–/–</sup> mice (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). The extent of pressure overload-induced fibrosis in heart sections and the mRNA levels of <italic>Col1a2</italic> and <italic>Col3a1</italic>, markers for fibrosis, in <italic>Ncoa4</italic><sup>–/–</sup> mice were lower than in <italic>Ncoa4</italic><sup>+/+</sup> mice (<xref ref-type="fig" rid="fig1">Figure 1D</xref> and <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). There were no differences in echocardiographic parameters between TAC-operated Myh6-Cre<sup>+</sup> and Myh6-Cre<sup>–</sup> mice 4 weeks after TAC (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>). Thus, the overexpression of Cre recombinase in the heart has no effect on pressure overload-induced cardiac remodeling. Taken together, NCOA4 deficiency attenuated pressure overload-induced cardiac remodeling, including cardiac hypertrophy and dysfunction, chamber dilation, and fibrosis.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Cardiomyocyte-specific <italic>Ncoa4</italic> ablation attenuated the development of pressure overload-induced heart failure.</title><p>The <italic>Ncoa4</italic><sup>+/+</sup> and <italic>Ncoa4<sup>–/–</sup></italic> mice were subjected to pressure overload by transverse aortic constriction (TAC) and analyzed 4 weeks after the operation. (<bold>A</bold>) Representative images of transthoracic M-mode echocardiographic tracing. Scale bars, 0.1 s and 2 mm, respectively. (<bold>B</bold>) Echocardiographic parameters of the mice (<italic>n</italic> = 10 biologically independent samples). LVIDd and LVIDs, end-diastolic and end-systolic left ventricular (LV) internal dimensions; IVSd, end-diastolic interventricular septum thickness; LVPWd, end-diastolic LV posterior wall thickness; FS, fractional shortening. (<bold>C</bold>) Physiological parameters of the mice (<italic>n</italic> = 10 biologically independent samples). (<bold>D</bold>) Representative images of the hematoxylin-eosin-stained (upper), Masson’s trichrome-stained (middle), and wheat germ agglutinin-stained (lower) heart sections. Scale bar, 50 μm. The upper and lower right graphs show the ratio of the fibrotic area to whole heart section and the cross-sectional area of cardiomyocytes, respectively (<italic>n</italic> = 5 biologically independent samples). The data were evaluated by one-way analysis of variance (ANOVA), followed by Tukey–Kramer’s post hoc test. <sup>*</sup>p&lt;0.05, <sup>**</sup>p&lt;0.001, <sup>***</sup>p&lt;0.0001. NS, p&gt;0.05. Exact p-values are provided in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig1">Figure 1</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-62174-fig1-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig1sdata2"><label>Figure 1—source data 2.</label><caption><title>Physiological and echocardiographic parameters in 8- to 10-week-old <italic>Ncoa4</italic><sup>+/+</sup> and <italic>Ncoa4<sup>–/–</sup></italic> mice at baseline.</title><p>BP, blood pressure; TL, tibia length; LV, left ventricle; LVIDd, end-diastolic left ventricular internal dimension; LVIDs, end-systolic left ventricular internal dimension; IVSd, end-diastolic interventricular septum thickness; LVPWd, end-diastolic left ventricular posterior wall thickness; FS, fractional shortening. The data are the mean ± SEM. <italic>n</italic> indicates the number of biologically independent samples. The data were evaluated by unpaired, two-tailed Student’s <italic>t</italic>-test.</p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-62174-fig1-data2-v1.docx"/></supplementary-material></p><p><supplementary-material id="fig1sdata3"><label>Figure 1—source data 3.</label><caption><title>Source data for data table provided in <xref ref-type="supplementary-material" rid="fig1sdata2">Figure 1—source data 2</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-62174-fig1-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62174-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Generation of cardiomyocyte-specific nuclear receptor coactivator 4 (NCOA4)-deficient mice.</title><p>(<bold>A</bold>) Targeted modification of the <italic>Ncoa4</italic> gene. Schematic structures of the wild-type genomic <italic>Ncoa4</italic> sequence, the targeting construct, the targeted allele, the floxed allele after flippase recognition target site (<italic>FRT</italic>)-mediated <italic>neomycin</italic>-resistance gene (<italic>Neo</italic>) deletion, and the deleted allele after Cre-mediated recombination are indicated from <italic>top</italic> to <italic>bottom</italic>. The <italic>black</italic> and <italic>white arrowheads</italic> indicate <italic>loxP</italic> and <italic>FRT</italic> sites, respectively. The <italic>neomycin</italic> resistance gene (<italic>PGK-Neo</italic> cassette) was inserted between exon six and the downstream <italic>loxP</italic> site. The diphtheria toxin A (<italic>DT</italic>) gene was positioned at the 3’ end of the targeting construct for negative selection. The <italic>bar</italic> labelled as ‘probe’ corresponds to the sequence used for Southern blotting. The scale bar indicates two kbp. (<bold>B</bold>) Genomic analysis of embryonic stem (ES) cells. To identify homologous recombinants, genomic DNA extracted from ES cells was digested with EcoRV and analyzed by Southern blotting with the 5’ and 3’ probe, respectively. Wild-type and targeted allele respectively showed 7748 and 6,172 bp using the 5’ probe (left) and 5269 and 6,924 bp using the 3’ probe (right). The ES cells with <italic>Ncoa4</italic>-floxed allele were injected into blastocysts to obtain <italic>Ncoa4</italic><sup>flox/</sup> mice. (<bold>C</bold>) Protein expression levels of NCOA4 in <italic>Ncoa4</italic><sup>+/+</sup> and <italic>Ncoa4</italic><sup>–/–</sup> hearts. Left ventricular homogenates from <italic>Ncoa4</italic><sup>+/+</sup> and <italic>Ncoa4</italic><sup>–/–</sup> mice were immunoprecipitated with anti-NCOA4 antibody, followed by Western blotting with the antibody. Densitometric analysis is shown. (<bold>D</bold>) mRNA expression levels of <italic>Ncoa4</italic>. The average value of NCOA4 (<bold>C</bold>) or <italic>Ncoa4</italic>-to-<italic>Gapdh</italic> ratio (<bold>D</bold>) in <italic>Ncoa4</italic><sup>+/+</sup> was set equal to 1. The values are presented as the mean ± SEM of 4 mice for protein expression and eight mice for mRNA expression in each group. The data were evaluated by unpaired, two-tailed Student’s <italic>t</italic>-test.</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-62174-fig1-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62174-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Cardiac remodeling markers in transverse aortic constriction (TAC)-operated <italic>Ncoa4</italic><sup>–/–</sup> mice.</title><p>The <italic>Ncoa4</italic><sup>+/+</sup> and <italic>Ncoa4</italic><sup>–/–</sup> mice were subjected to TAC. The levels of mRNA were analyzed 4 weeks after the operation (<italic>n</italic> = 8 biologically independent samples). <italic>Gapdh</italic> mRNA was used as the loading control. The values are presented as the mean ± SEM. The data were evaluated by one-way analysis of variance (ANOVA), followed by Tukey–Kramer’s post hoc test. <sup>*</sup>p&lt;0.05, <sup>**</sup>p&lt;0.001, <sup>***</sup>p&lt;0.0001. NS, p&gt;0.05. Exact p-values are provided in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p><p><supplementary-material id="fig1s2sdata1"><label>Figure 1—figure supplement 2—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-62174-fig1-figsupp2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62174-fig1-figsupp2-v1.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>Myh6-Cre transgene does not alter the heart response to pressure overload stress.</title><p>The Myh6-Cre<sup>–</sup> and Myh6-Cre mice were subjected to TAC and analyzed 4 weeks after the operation. Echocardiographic parameters of the mice (<italic>n</italic> = 4 biologically independent samples) are shown. LVIDd and LVIDs, end-diastolic and end-systolic left ventricular (LV) internal dimensions; FS, fractional shortening. The values are presented as the mean ± SEM. The data were evaluated by unpaired, two-tailed Student’s <italic>t</italic>-test. NS, p&gt;0.05. Exact p-values are provided in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p><p><supplementary-material id="fig1s3sdata1"><label>Figure 1—figure supplement 3—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-62174-fig1-figsupp3-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62174-fig1-figsupp3-v1.tif"/></fig></fig-group></sec><sec id="s2-3"><title>Attenuation of upregulation of ferritinophagy in pressure-overloaded NCOA4-deficient hearts</title><p>The level of ferritinophagy in pressure-overloaded hearts was then evaluated 4 weeks after TAC. The protein level of FTH1 was decreased in <italic>Ncoa4</italic><sup>+/+</sup> hearts compared to both sham-operated <italic>Ncoa4</italic><sup>+/+</sup> and TAC-operated <italic>Ncoa4</italic><sup>–/–</sup> hearts (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). However, the mRNA level of FTH1 was also decreased in <italic>Ncoa4</italic><sup>+/+</sup> hearts (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). To clarify the ferritinophagic activity, we evaluated the cardiac phenotypes during an earlier time course after pressure overload when the secondary effect to cardiac remodeling was minimal. Cardiac dysfunction and LV chamber dilation were observed in wild-type <italic>Ncoa4</italic><sup>+/+</sup> hearts (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). Both TAC-operated <italic>Ncoa4</italic><sup>+/+</sup> and <italic>Ncoa4</italic><sup>–/–</sup> mice showed decreased fractional shortening 3 days after surgery compared to the corresponding sham-operated group. However, there was no significant difference in fractional shortening between TAC-operated <italic>Ncoa4</italic><sup>+/+</sup> and <italic>Ncoa4</italic><sup>–/–</sup> mice, suggesting mild cardiac dysfunction observed in both groups 3 days after TAC was due to acute response to pressure overload. The protein level of FTH1 decreased from postoperative day 5 compared to sham-operated hearts, while the level of <italic>Fth1</italic> mRNA increased 5 and 7 days after TAC and decreased 4 weeks after TAC (<xref ref-type="fig" rid="fig2">Figure 2C and D</xref>). NCOA4 is responsible for the selective targeting of the ferritin complex to autophagosomes. In the TAC-operated hearts, the number of LC3B (a marker of an autophagosome)- and FTH1-positive dots increased after postoperative day 5 and then declined 4 weeks after TAC (day 7 versus 4 weeks, p&lt;0.0001), and that of LAMP2a (a marker of a lysosome)- and FTH1-positive dots increased 7 days after TAC (<xref ref-type="fig" rid="fig2">Figure 2E,F,G and H</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>The time course of ferritinophagy in the heart after transverse aortic constriction (TAC).</title><p>(<bold>A</bold>) Western blot analysis of FTH1 in <italic>Ncoa4</italic><sup>+/+</sup> and <italic>Ncoa4</italic><sup>–/–</sup> hearts 4 weeks after TAC. GAPDH was used as the loading control. The right-hand graphs show the densitometric analysis. The average value for sham-operated <italic>Ncoa4</italic><sup>+/+</sup> hearts was set to 1 (biologically independent samples: <italic>n</italic> = 6). (<bold>B</bold>) mRNA expression of <italic>Fth1</italic> in the heart 4 weeks after TAC. <italic>Gapdh</italic> mRNA was used as the loading control. The average value for sham-operated <italic>Ncoa4</italic><sup>+/+</sup> hearts was set to 1 (biologically independent samples: <italic>n</italic> = 8). (<bold>C–H</bold>) The <italic>Ncoa4</italic><sup>+/+</sup> mice were subjected to TAC and analyzed 3 days after sham operation and 3, 5, and 7 days and 4 weeks after the operation. (<bold>C</bold>) Heart homogenates after TAC were subjected to western blot analysis using anti-FTH1 antibody (<italic>n</italic> = 5 biologically independent samples for each group). GAPDH was used as the loading control. (<bold>D</bold>) Cardiac <italic>Fth1</italic> mRNA levels after TAC (<italic>n</italic> = 5 biologically independent samples). <italic>Gapdh</italic> mRNA was used as the loading control. (<bold>E and F</bold>) Immunofluorescence analysis of LC3B (green) and FTH1 (red) in the heart after TAC (<italic>n</italic> = 5 biologically independent samples). (<bold>G and H</bold>) Immunofluorescence analysis of LAMP2a (green) and FTH1 (red) in the heart after TAC (<italic>n</italic> = 5 biologically independent samples). Scale bar, 5 μm in (<bold>E</bold>) and (<bold>G</bold>). Arrows indicate double-positive dots. The values are presented as the mean ± SEM. The data were evaluated by one-way analysis of variance (ANOVA), followed by Tukey–Kramer’s post hoc test. <sup>*</sup>p&lt;0.05, <sup>**</sup>p&lt;0.001, <sup>***</sup>p&lt;0.0001. NS, p&gt;0.05 versus sham-operated group. Exact p-values are provided in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig2">Figure 2</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-62174-fig2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62174-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Echocardiographic parameter aftertransverse aortic constriction (TAC).</title><p>Time course of changes in the echocardiographic parameters of left ventricular (LV) fractional shortening (FS), the end-diastolic LV internal dimension (LVIDd) and the end-systolic LV internal dimension (LVIDs). Echocardiographic analysis on <italic>Ncoa4</italic><sup>+/+</sup> and <italic>Ncoa4</italic><sup>–/–</sup> mice were performed before (pre) and 3, 5, and 7 days after TAC (n = 3 biologically independent samples). The values are presented as the mean ± SEM. Two-way analysis of variance (ANOVA) followed by Tukey's multiple comparisons test was used. <sup>*</sup>p&lt;0.05, <sup>**</sup>p&lt;0.001, <sup>***</sup>p&lt;0.0001. p&gt;0.05, sham-operated <italic>Ncoa4<sup>+/+</sup></italic> versus TAC-operated <italic>Ncoa4<sup>+/+</sup></italic>. <sup>†</sup>p&lt;0.05, <sup>††</sup>p&lt;0.001, <sup>†††</sup>p&lt;0.0001. p&gt;0.05, sham-operated <italic>Ncoa4</italic><sup>–/–</sup> versus TAC-operated <italic>Ncoa4</italic><sup>–/–</sup>. <sup>‡</sup>p&lt;0.05, <sup>‡‡</sup>p&lt;0.001, <sup>‡‡‡</sup>p&lt;0.0001. p&gt;0.05, TAC-operated <italic>Ncoa4<sup>+/</sup></italic><sup>+</sup> versus TAC-operated <italic>Ncoa4</italic><sup>–/–</sup>. Exact p-values are provided in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-62174-fig2-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62174-fig2-figsupp1-v1.tif"/></fig></fig-group><p>The extent of ferritinophagy in <italic>Ncoa4</italic><sup>+/+</sup> and <italic>Ncoa4</italic><sup>–/–</sup> mice was then evaluated 7 days after TAC. The ablation of <italic>Ncoa4</italic> attenuated the downregulation of FTH1 protein and upregulation of <italic>Fth1</italic> mRNA in TAC-operated <italic>Ncoa4</italic><sup>+/+</sup> hearts (<xref ref-type="fig" rid="fig3">Figure 3A and B</xref>). The number of LC3B- and FTH1-positive dots and the number of LAMP2a- and FTH1-positive dots decreased in TAC-operated <italic>Ncoa4</italic><sup>–/–</sup> hearts compared to <italic>Ncoa4</italic><sup>+/+</sup> hearts (<xref ref-type="fig" rid="fig3">Figure 3C,D,E and F</xref>).</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Ablation of <italic>Ncoa4</italic> in cardiomyocytes showed defective ferritinophagy.</title><p>(<bold>A</bold>) Western blot analysis of FTH1 in <italic>Ncoa4</italic><sup>+/+</sup> and <italic>Ncoa4</italic><sup>–/–</sup> hearts 1 week after transverse aortic constriction (TAC). GAPDH was used as the loading control. The right-hand graphs show the densitometric analysis. The average value for sham-operated <italic>Ncoa4</italic><sup>+/+</sup> hearts was set to 1 (biologically independent samples: <italic>n</italic> = 5). (<bold>B</bold>) mRNA expression of <italic>Fth1</italic> in the heart 1 week after TAC. <italic>Gapdh</italic> mRNA was used as the loading control. The average value for sham-operated <italic>Ncoa4</italic><sup>+/+</sup> hearts was set to 1 (biologically independent samples: <italic>n</italic> = 5). (<bold>C and D</bold>) Immunofluorescence analysis of LC3B (green) and FTH1 (red) in the heart 1 week after TAC. The number of LC3B- and FTH1-positive dots is shown in (<bold>D</bold>). (<bold>E and F</bold>) Immunofluorescence analysis of LAMP2a (green) and FTH1 (red) in the heart 1 week after TAC. The number of LAPM2a- and FTH1-positive dots is shown in (<bold>F</bold>). In (<bold>C</bold>) and (<bold>E</bold>), images of the square in the merged images are shown at higher magnification in the right three columns. Scale bar, 5 μm. Arrows indicate double-positive dots. The data were evaluated by one-way analysis of variance (ANOVA), followed by Tukey–Kramer’s post hoc test. <sup>*</sup>p&lt;0.05, <sup>**</sup>p&lt;0.001, <sup>***</sup>p&lt;0.0001. NS, p&gt;0.05. Exact p-values are provided in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig3">Figure 3</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-62174-fig3-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62174-fig3-v1.tif"/></fig></sec><sec id="s2-4"><title>Erythropoiesis in NCOA4-deficient mice</title><p>To determine whether the failure of cardiomyocyte-specific NCOA4-deficient mice to degrade ferritin in cardiomyocytes affects erythropoiesis, as reported in global NCOA4-deficient mice (<xref ref-type="bibr" rid="bib6">Bellelli et al., 2016</xref>), we explored the effect of NCOA4 deficiency in the heart on red blood cell parameters (<xref ref-type="supplementary-material" rid="fig4sdata2">Figure 4—source data 2</xref>). There were no significant differences in hematological parameters, serum iron, and transferrin saturation between any groups. Pressure overload reduced serum ferritin compared to the corresponding sham-operated group, but there was no significant difference between TAC-operated <italic>Ncoa4</italic><sup>+/+</sup> and <italic>Ncoa4</italic><sup>–/–</sup> mice. Serum ferritin is both a marker of liver iron stores and acute inflammatory response (<xref ref-type="bibr" rid="bib17">Kell and Pretorius, 2014</xref>). TAC decreased the level of total non-heme iron in both <italic>Ncoa4</italic><sup>+/+</sup> and <italic>Ncoa4</italic><sup>–/–</sup> livers, but there was no significant difference in the level between <italic>Ncoa4</italic><sup>+/+</sup> and <italic>Ncoa4</italic><sup>–/–</sup> mice (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). TAC increased the serum IL-6 level in both <italic>Ncoa4</italic><sup>+/+</sup> and <italic>Ncoa4</italic><sup>–/–</sup> mice, which was higher in <italic>Ncoa4<sup>+/</sup></italic><sup>+</sup> than that in <italic>Ncoa4</italic><sup>–/–</sup> (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>). It has been reported that the serum level of IL-6 in the patients with heart failure is related to its severity (<xref ref-type="bibr" rid="bib16">Hirota et al., 2004</xref>). Thus, the reduced level of serum ferritin level in TAC-operated mice may be due to the reduction in liver iron stores.</p></sec><sec id="s2-5"><title>Iron metabolism in pressure-overloaded NCOA4-deficient hearts</title><p>Next, we assessed the effect of pressure overload on iron metabolism in the heart (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Increased free ferrous iron plays a critical role in the Fenton reaction during iron-dependent necrosis. Pressure overload decreased the total non-heme iron content in both <italic>Ncoa4</italic><sup>+/+</sup> and <italic>Ncoa4</italic><sup>–/–</sup> hearts. The level of ferrous iron in <italic>Ncoa4</italic><sup>+/+</sup> hearts was higher than that in <italic>Ncoa4</italic><sup>–/–</sup> hearts under pressure overload, whereas the level of ferric iron was lower in <italic>Ncoa4</italic><sup>+/+</sup> hearts than in <italic>Ncoa4</italic><sup>–/–</sup> hearts. The ratio of ferrous iron to FTH1, which represents the non-binding fraction of ferrous iron to FTH1, was higher in TAC-operated <italic>Ncoa4</italic><sup>+/+</sup> hearts than in the sham-operated controls and TAC-operated <italic>Ncoa4</italic><sup>–/–</sup> hearts, suggesting free ferrous iron overload in TAC-operated <italic>Ncoa4</italic><sup>+/+</sup> hearts. When iron is limited, regulatory proteins (IRPs) bind to iron regulatory elements (IREs) found in untranslated regions (UTR) of mRNA involved in iron transport and storage (<xref ref-type="bibr" rid="bib1">Anderson et al., 2012</xref>). IRP binding to IREs found in the 5’ UTR of mRNA encoding FTH1, FTL and ferroportin 1 (exports iron out of the cell, also known as solute carrier family 40 member 1; SLC40A1) blocks the initiation of translation. IREs, found in the 3’ UTR of transferrin receptor 1 (TFRC; the membrane receptor for iron), divalent metal iron transport (solute carrier family 11 member 2; SLC11A2), cell division cycle 14A (CDC14A), and CDC binding protein kinase alpha (CDC42BPA), bind IRPs to stabilize the mRNA by inhibiting nuclease digestion. The levels of proteins related to intracellular iron metabolism such as IREB2, SLC40A1, and TFRC showed no differences between TAC-operated groups (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A</xref>). There were no significant differences in the mRNA levels of <italic>Tfrc</italic>, <italic>Slc11a2</italic>, <italic>Cdc14a</italic>, and <italic>Cdc42bpa</italic> between TAC-operated groups (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2B</xref>). The binding of IRP with the 5’ UTR of <italic>Slc40a1</italic> exhibited no difference between TAC-operated groups (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2C</xref>). These suggest that IRP system is impaired in TAC-operated <italic>Ncoa4</italic><sup>+/+</sup> mice.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>The effect of <italic>Ncoa4</italic> ablation on the pathways to iron-dependent cell death.</title><p>(<bold>A</bold>) Tissue levels of total non-heme, ferrous, and ferric iron in <italic>Ncoa4</italic><sup>+/+</sup> and <italic>Ncoa4</italic><sup>–/–</sup> hearts 4 weeks after transverse aortic constriction (TAC) (<italic>n</italic> = 6 biologically independent samples). The ratio of the ferrous iron level to the FTH1 protein level is shown in the right-most panel. The FTH1 protein level for sham-operated <italic>Ncoa4</italic><sup>+/+</sup> estimated as Western blot analysis in hearts was set to 1. (<bold>B</bold>) Malondialdehyde (MDA) levels in heart homogenates (<italic>n</italic> = 5 biologically independent samples). (<bold>C</bold>) <italic>Ptgs2</italic> mRNA levels in the heart (<italic>n</italic> = 8 biologically independent samples). (<bold>D</bold>) Serum troponin T (TnT) levels (<italic>n</italic> = 8 biologically independent samples). (<bold>E</bold>) Glutathione peroxidase 4 (GPX4) levels in the heart homogenates. The right panel shows the ratio of GPX4 to GAPDH (<italic>n</italic> = 6 biologically independent samples). (<bold>F</bold>) The levels of total glutathione (GSH+GSSG), reduced (GSH) and oxidized (GSSG) glutathione and the ratio of GSH to GSSG in heart homogenates (<italic>n</italic> = 5 biologically independent samples). GSH levels were calculated by subtracting GSSG from total glutathione. (<bold>G</bold>) Cardiac glutamine levels (<italic>n</italic> = 5 biologically independent samples). The data were evaluated by one-way analysis of variance (ANOVA), followed by Tukey–Kramer’s post hoc test. <sup>*</sup>p&lt;0.05, <sup>**</sup>p&lt;0.001, <sup>***</sup>p&lt;0.0001. NS, p&gt;0.05. Exact p-values are provided in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig4">Figure 4</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-62174-fig4-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4—source data 2.</label><caption><title>Hematological parameters and red cell indices in <italic>Ncoa4</italic><sup>+/+</sup> and <italic>Ncoa4<sup>–/–</sup></italic> mice.</title><p>PCV, packed cell volume; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; CH, hemoglobin concentration. Data are the mean ± SEM. <italic>n</italic> indicates the number of biologically independent samples. The data were evaluated by one-way analysis of variance (ANOVA), followed by Tukey–Kramer’s post hoc test. <sup>*</sup>p=0.0418 and <sup>**</sup>p=0.0108 versus the corresponding sham-operated group. Exact p-values are provided in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-62174-fig4-data2-v1.docx"/></supplementary-material></p><p><supplementary-material id="fig4sdata3"><label>Figure 4—source data 3.</label><caption><title>Source data for data table provided in <xref ref-type="supplementary-material" rid="fig4sdata2">Figure 4—source data 2</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-62174-fig4-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62174-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Liver iron store and serum inflammatory cytokine in <italic>Ncoa4</italic><sup>+/+</sup> and <italic>Ncoa4<sup>–/–</sup></italic> mice.</title><p>(<bold>A</bold>) Tissue levels of total non-heme iron in <italic>Ncoa4<sup>+/+</sup></italic> and <italic>Ncoa4<sup>–/–</sup></italic> livers 4 weeks after TAC (n = 6 biologically independent samples). (<bold>B</bold>) Serum interleukin 6 (IL-6) levels (<italic>n</italic> = 8 biologically independent samples). The values are presented as the mean ± SEM. The data were evaluated by one-way analysis of variance (ANOVA), followed by Tukey–Kramer’s post hoc test. <sup>*</sup>p&lt;0.05, <sup>**</sup>p&lt;0.001, <sup>***</sup>p&lt;0.0001. NS, p&gt;0.05. Exact p-values are provided in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p><p><supplementary-material id="fig4s1sdata1"><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-62174-fig4-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62174-fig4-figsupp1-v1.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Iron regulating proteins in transverse aortic constriction (TAC)-operated <italic>Ncoa4</italic><sup>–/–</sup> hearts.</title><p>(<bold>A</bold>) Homogenates from the heart 4 weeks after TAC were subjected to western blot analysis using antibodies against iron-responsive element-binding protein 2 (IREB2), ferroportin 1 (SLC40A1), and transferrin receptor 1 (TFRC) (<italic>n</italic> = 6 biologically independent samples). GAPDH was used as the loading control. (<bold>B</bold>) The levels of mRNA were analyzed 4 weeks after the operation (<italic>n</italic> = 8 biologically independent samples). <italic>Gapdh</italic> mRNA was used as the loading control. (<bold>C</bold>) IRP activation in <italic>Ncoa4<sup>+/</sup></italic><sup>+</sup> and <italic>Ncoa4<sup>–/–</sup></italic> hearts. The activation of IRP was analyzed by EMSA. Protein homogenates from mouse heart were incubated with the 5’ UTR of mouse <italic>Slc40a1</italic> containing IRE and subjected to electrophoresis. (<italic>n</italic> = 3 biologically independent samples). The values are presented as the mean ± SEM. The data were evaluated by one-way analysis of variance (ANOVA), followed by Tukey–Kramer’s post hoc test. NS, p&gt;0.05. Exact p-values are provided in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p><p><supplementary-material id="fig4s2sdata1"><label>Figure 4—figure supplement 2—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-62174-fig4-figsupp2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62174-fig4-figsupp2-v1.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 3.</label><caption><title>Lipid reactive oxygen species and anti-oxidant proteins in <italic>Ncoa4</italic><sup>–/–</sup> hearts 4 weeks after transverse aortic constriction (TAC).</title><p>(<bold>A</bold>) 4-Hydroxy-2-noneal (HNE) staining of heart sections. Scale bar, 50 μm. The right panel shows the quantitative analysis of 4-HNE-positive area to whole heart section (<italic>n</italic> = 5 biologically independent samples). (<bold>B</bold>) Homogenates from the heart were subjected to western blot analysis using antibodies against superoxide dismutase 2 (SOD2) and heme oxygenase 1 (HO-1) (<italic>n</italic> = 6 biologically independent samples). GAPDH was used as the loading control. The values are presented as the mean ± SEM. The data were evaluated by one-way analysis of variance (ANOVA), followed by Tukey–Kramer’s post hoc test. <sup>*</sup>p&lt;0.05. NS, p&gt;0.05. Exact p-values are provided in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p><p><supplementary-material id="fig4s3sdata1"><label>Figure 4—figure supplement 3—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-62174-fig4-figsupp3-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62174-fig4-figsupp3-v1.tif"/></fig><fig id="fig4s4" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 4.</label><caption><title>The system Xc<sup>-</sup>/glutathione axis and glutaminolysis pathway in transverse aortic constriction (TAC)-operated <italic>Ncoa4<sup>–/–</sup></italic> hearts.</title><p>(<bold>A</bold>) The mRNA expression level of <italic>Slc7a11</italic> in the heart 4 weeks after TAC (<italic>n</italic> = 8 biologically independent samples). <italic>Gapdh</italic> mRNA was used as the loading control. (<bold>B</bold>) The cystine concentration in the heart was analyzed by high–performance liquid chromatography (HPLC) (<italic>n</italic> = 4 for sham-operated <italic>Ncoa4</italic><sup>+/+</sup>, <italic>n</italic> = 5 for TAC-operated <italic>Ncoa4</italic><sup>+/+</sup>, sham-operated <italic>Ncoa4</italic><sup>–/–</sup>, and TAC-operated <italic>Ncoa4</italic><sup>–/–</sup> biologically independent samples). (<bold>C</bold>) Cardiac glutamate levels (<italic>n</italic> = 5 biologically independent samples). (<bold>D</bold>) The mRNA expression levels of <italic>Slc38a1</italic>, <italic>Slc1a5</italic>, <italic>Slc7a5</italic>, <italic>Gls1,</italic> and <italic>Gls2</italic> in the hearts 4 weeks after TAC (<italic>n</italic> = 8 biologically independent samples). <italic>Gapdh</italic> mRNA was used as the loading control. The values are presented as the mean ± SEM. The data were evaluated by one-way analysis of variance (ANOVA), followed by Tukey–Kramer’s post hoc test. <sup>*</sup>p&lt;0.05, <sup>***</sup>p&lt;0.0001. NS, p&gt;0.05. Exact p-values are provided in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p><p><supplementary-material id="fig4s4sdata1"><label>Figure 4—figure supplement 4—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-62174-fig4-figsupp4-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62174-fig4-figsupp4-v1.tif"/></fig></fig-group></sec><sec id="s2-6"><title>Lipid oxidation in pressure-overloaded NCOA4-deficient hearts</title><p>Lipid peroxidation is a hallmark of iron-dependent necrosis (<xref ref-type="bibr" rid="bib7">Dixon et al., 2012</xref>). In <italic>Ncoa4</italic><sup>+/+</sup> hearts, pressure overload increased the levels of malondialdehyde (MDA) and 4-hydroxy-2-nonenal (4-HNE)-positive area; markers for lipid peroxidation (<xref ref-type="bibr" rid="bib5">Ayala et al., 2014</xref>; <xref ref-type="fig" rid="fig4">Figure 4B</xref> and <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3A</xref>). In contrast, these markers were attenuated in <italic>Ncoa4</italic><sup>–/–</sup> hearts. <italic>Ptgs2</italic> mRNA, a putative marker for ferroptosis (<xref ref-type="bibr" rid="bib38">Yang et al., 2014</xref>), was increased in TAC-operated <italic>Ncoa4</italic><sup>+/+</sup> hearts but not in <italic>Ncoa4</italic><sup>–/–</sup> hearts (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). There were no significant differences in the antioxidant protein levels of superoxide dismutase 2 and heme oxygenase 1 between any groups (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3B</xref>). The increase in serum troponin T (TnT), a marker for necrotic cell death, in TAC-operated <italic>Ncoa4</italic><sup>+/+</sup> mice was significantly attenuated by <italic>Ncoa4</italic> ablation (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). Taken together, these results show that iron-dependent necrosis plays an important role in the development of pressure overload-induced heart failure.</p></sec><sec id="s2-7"><title>Glutathione and glutamine metabolism in pressure-overloaded NCOA4-deficient hearts</title><p>The GPX4 protein level was upregulated in TAC-operated <italic>Ncoa4</italic><sup>+/+</sup> hearts compared to the corresponding controls, while ablation of <italic>Ncoa4</italic> suppressed the pressure overload-induced induction of GPX4 (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). The levels of total and reduced glutathione (GSH) decreased and oxidized glutathione (GSSG) increased in TAC-operated <italic>Ncoa4</italic><sup>+/+</sup> hearts, resulting in a decreased GSH to GSSG ratio in <italic>Ncoa4</italic> <sup>/</sup> hearts (<xref ref-type="fig" rid="fig4">Figure 4F</xref>). <italic>Ncoa4</italic> ablation normalized the ratio to the sham control level. The cysteine-glutamate antiporter (system Xc<sup>–</sup>, also known as solute carrier family 7 member 11; SLC7A11) is a key regulator for cystine uptake in cell survival against ferroptosis (<xref ref-type="bibr" rid="bib13">Gao et al., 2015</xref>). There was no significant difference in the level of <italic>Slc7a11</italic> mRNA or cardiac cystine between TAC-operated <italic>Ncoa4</italic><sup>+/+</sup> and <italic>Ncoa4</italic><sup>–/–</sup> mice (<xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4A and B</xref>). The level of glutamate in TAC-operated <italic>Ncoa4</italic><sup>+/+</sup> hearts was lower than that in sham-operated <italic>Ncoa4</italic><sup>+/+</sup> or TAC-operated <italic>Ncoa4</italic><sup>–/–</sup> mice (<xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4C</xref>). L-glutamine uptake is mainly dependent on the receptors SLC38A1, SLC1A5, and SLC7A5 (<xref ref-type="bibr" rid="bib22">McGivan and Bungard, 2007</xref>), and L-glutamine is converted into glutamate by glutaminase (GLS1 and GLS2). The cardiac glutamine level decreased in TAC-operated <italic>Ncoa4</italic><sup>+/+</sup> hearts compared to the corresponding sham-operated mice and was lower than that in TAC-operated <italic>Ncoa4</italic><sup>–/–</sup> hearts (<xref ref-type="fig" rid="fig4">Figure 4G</xref>). There were no significant differences in the mRNA levels of the glutamine transporters or glutaminases between TAC-operated groups (<xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4D</xref>). The changes in glutathione metabolism and glutaminolysis in TAC-operated <italic>Ncoa4</italic><sup>+/+</sup> hearts were not as seen in typical ferroptosis.</p></sec><sec id="s2-8"><title>Isoproterenol-induced cell death in isolated adult cardiomyocytes</title><p>The lipid ROS and labile iron pool during iron-dependent necrosis were further estimated using adult cardiomyocytes isolated from <italic>Ncoa4</italic><sup>+/+</sup> and <italic>Ncoa4</italic><sup>–/–</sup> hearts. The activation of neurohumoral factors such as catecholamine plays an important role in the pathogenesis of heart failure (<xref ref-type="bibr" rid="bib33">Shah and Mann, 2011</xref>). The synthetic small-molecule compound erastin inhibits the activity of cysteine–glutamate antiporter, leading to the depletion of GSH (<xref ref-type="bibr" rid="bib7">Dixon et al., 2012</xref>). High-throughput screening has identified ferrostatin-1 as a potent inhibitor of the accumulation of lipid ROS (<xref ref-type="bibr" rid="bib7">Dixon et al., 2012</xref>; <xref ref-type="bibr" rid="bib11">Friedmann Angeli et al., 2014</xref>; <xref ref-type="bibr" rid="bib34">Skouta et al., 2014</xref>). Erastin or isoproterenol induced cell death in <italic>Ncoa4</italic><sup>+/+</sup> cardiomyocytes, while this occurred to a lesser extent in <italic>Ncoa4</italic><sup>–/–</sup> cardiomyocytes (<xref ref-type="fig" rid="fig5">Figure 5A</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>). Ferrostatin-1 inhibited both erastin- and isoproterenol-induced cardiomyocyte cell death. Treatment of <italic>Ncoa4</italic><sup>+/+</sup> cardiomyocytes with either erastin or isoproterenol resulted in an increase in the cellular and lipid ROS levels, as estimated using the fluorescent probes H2DCFDA and C11-BODIPY, respectively (<xref ref-type="bibr" rid="bib7">Dixon et al., 2012</xref>; <xref ref-type="fig" rid="fig5">Figure 5B and C</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B and C</xref>). The application of either ferrostatin-1 or <italic>Ncoa4</italic> ablation prevented the generation of erastin- or isoproterenol-induced cellular and lipid ROS, which is in agreement with a previous report that used HT-1080 cells (<xref ref-type="bibr" rid="bib7">Dixon et al., 2012</xref>). The labile iron pool level was measured using calcein-acetoxymethyl ester (<xref ref-type="bibr" rid="bib39">Yoshida et al., 2019</xref>). Erastin and isoproterenol could both increase the level of the labile iron pool in <italic>Ncoa4</italic><sup>+/+</sup> cardiomyocytes, which was attenuated by treatment with ferrostatin-1 (<xref ref-type="bibr" rid="bib23">Miotto et al., 2020</xref>; <xref ref-type="fig" rid="fig5">Figure 5D</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D</xref>). <italic>Ncoa4</italic> ablation was effective in reducing the erastin- or isoproterenol-induced upregulation of the labile iron pool. Isoproterenol decreased the protein level of FTH1 in an NCOA4-dependent manner (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). A small molecule, RSL3, is another ferroptosis inducer, which binds and inhibits GPX4 (<xref ref-type="bibr" rid="bib38">Yang et al., 2014</xref>). RSL3 induced cardiomyocyte death, which was attenuated by <italic>Ncoa4</italic> ablation or ferrostatin-1 treatment (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Isoproterenol induces iron-dependent cell death in isolated cardiomyocytes.</title><p>(<bold>A</bold>) Cell death assay. Cell death was estimated using a Live/Dead Viability/Cytotoxicity Assay Kit. Isolated mouse cardiomyocytes from <italic>Ncoa4</italic><sup>+/+</sup> and <italic>Ncoa4</italic><sup>–/–</sup> hearts were treated with the indicated concentrations of isoproterenol (Iso) with or without ferrostatin-1 (Fer-1) for 4 hr. Calcein-AM (green) is retained in live cells, while ethidium homodimer produces red fluorescence in dead cells. Scale bar, 100 μm. The percentage of dead cells is shown in the middle left-hand graphs (<italic>n</italic> = 5 biologically independent samples). (<bold>B and C</bold>) The accumulation of cellular (<bold>B</bold>) and lipid (<bold>C</bold>) reactive oxygen species (ROS) were assessed by H2DCFDA and C11-BODIPY, respectively (<italic>n</italic> = 5 biologically independent samples). (<bold>D</bold>) The labile iron pool was measured using the calcein-AM method in isolated mouse cardiomyocytes (<italic>n</italic> = 5 biologically independent samples). (<bold>E</bold>) Western blot analysis of FTH1 in isolated mouse cardiomyocytes from <italic>Ncoa4</italic><sup>+/+</sup> and <italic>Ncoa4</italic><sup>–/–</sup> hearts. GAPDH was used as the loading control. The right-hand graphs show the densitometric analysis (<italic>n</italic> = 5 biologically independent samples). The average value for vehicle-treated without ferrostatin-1 <italic>Ncoa4</italic><sup>+/+</sup> cardiomyocytes was set to 1. The values are presented as the mean ± SEM. Two-way analysis of variance (ANOVA) followed by Tukey's multiple comparisons test was used. <sup>*</sup>p&lt;0.05, <sup>**</sup>p&lt;0.001, <sup>***</sup>p&lt;0.0001. NS, p&gt;0.05 versus <italic>Ncoa4<sup>+/</sup></italic><sup>+</sup> control without ferrostatin-1 treatment. <sup>†</sup>p&lt;0.05, <sup>††</sup>p&lt;0.001, <sup>†††</sup>p&lt;0.0001. NS, p&gt;0.05 versus the corresponding group without ferrostatin-1 treatment. <sup>‡</sup>p&lt;0.05, <sup>‡‡</sup>p&lt;0.001, <sup>‡‡‡</sup>p&lt;0.0001. NS, p&gt;0.05 versus the corresponding <italic>Ncoa4<sup>+/+</sup></italic>. Exact p-values are provided in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig5">Figure 5</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-62174-fig5-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62174-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Erasin induces cell death in isolated cardiomyocytes.</title><p>(<bold>A</bold>) Cell death assay. Cell death was estimated using a Live/Dead Viability/Cytotoxicity Assay Kit. Isolated mouse cardiomyocytes from <italic>Ncoa4</italic><sup>+/+</sup> and <italic>Ncoa4</italic><sup>–/–</sup> hearts were treated with the indicated concentrations of erastin (Era) with or without ferrostatin-1 (Fer-1) for 4 hr. Calcein-AM (green) is retained in live cells, while ethidium homodimer produces red fluorescence in dead cells. Scale bar, 100 μm. The percentage of dead cells is shown in the middle left-hand graphs (<italic>n</italic> = 5 biologically independent samples). (<bold>B and C</bold>) The accumulation of cellular (<bold>B</bold>) and lipid (<bold>C</bold>) reactive oxygen species (ROS) were assessed by H2DCFDA and C11-BODIPY, respectively (<italic>n</italic> = 5 biologically independent samples). (<bold>D</bold>) The labile iron pool was measured using the calcein-AM method in isolated mouse cardiomyocytes (<italic>n</italic> = 5 biologically independent samples). The average value for vehicle-treated without ferrostatin-1 <italic>Ncoa4</italic><sup>+/+</sup> cardiomyocytes was set to 1. The values are presented as the mean ± SEM. Two-way analysis of variance (ANOVA) followed by Tukey's multiple comparisons test was used. <sup>*</sup>p&lt;0.05, <sup>**</sup>p&lt;0.001, <sup>***</sup>p&lt;0.0001. NS, p&gt;0.05 versus <italic>Ncoa4<sup>+/+</sup></italic> control without ferrostatin-1 treatment. <sup>†</sup>p&lt;0.05, <sup>††</sup>p&lt;0.001, <sup>†††</sup>p&lt;0.0001. NS, p&gt;0.05 versus the corresponding group without ferrostatin-1 treatment. <sup>‡</sup>p&lt;0.05, <sup>‡‡</sup>p&lt;0.001, <sup>‡‡‡</sup>p&lt;0.0001. NS, p&gt;0.05 versus the corresponding <italic>Ncoa4<sup>+/+</sup></italic>. Exact p-values are provided in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p><p><supplementary-material id="fig5s1sdata1"><label>Figure 5—figure supplement 1—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-62174-fig5-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62174-fig5-figsupp1-v1.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>RSL3 induces cell death in isolated cardiomyocytes.</title><p>Cell death assay. Cell death was estimated using a Live/Dead Viability/Cytotoxicity Assay Kit. Isolated mouse cardiomyocytes from <italic>Ncoa4</italic><sup>+/+</sup> and <italic>Ncoa4</italic><sup>–/–</sup> hearts were treated with the indicated concentrations of RSL3 with or without ferrostatin-1 (Fer-1) for 4 hr. Calcein-AM (green) is retained in live cells, while ethidium homodimer produces red fluorescence in dead cells. Scale bar, 100 μm. The percentage of dead cells is shown in the graphs (<italic>n</italic> = 5 biologically independent samples). The values are presented as the mean ± SEM. Two-way analysis of variance (ANOVA) followed by Tukey's multiple comparisons test was used. <sup>*</sup>p&lt;0.05, <sup>**</sup>p&lt;0.001, <sup>***</sup>p&lt;0.0001. NS, p&gt;0.05 versus <italic>Ncoa4<sup>+/+</sup></italic> control without ferrostatin-1 treatment. <sup>†</sup>p&lt;0.05, <sup>††</sup>p&lt;0.001, <sup>†††</sup>p&lt;0.0001. NS, p&gt;0.05 versus the corresponding group without ferrostatin-1 treatment. <sup>‡</sup>p&lt;0.05, <sup>‡‡</sup>p&lt;0.001, <sup>‡‡‡</sup>p&lt;0.0001. NS, p&gt;0.05 versus the corresponding <italic>Ncoa4<sup>+/+</sup></italic>. Exact p-values are provided in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p><p><supplementary-material id="fig5s2sdata1"><label>Figure 5—figure supplement 2—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-62174-fig5-figsupp2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62174-fig5-figsupp2-v1.tif"/></fig></fig-group></sec><sec id="s2-9"><title>Attenuation of the development of cardiac remodeling by ferrostatin-1</title><p>To examine the involvement of iron-dependent necrosis in the pathogenesis of heart failure and whether iron-dependent necrosis is a therapeutic target for the disease, wild-type C57BL/6J mice received an intraperitoneal daily injection of ferrostatin-1. Four weeks after TAC, saline-administered mice exhibited LV chamber dilation and cardiac dysfunction (<xref ref-type="fig" rid="fig6">Figure 6A and B</xref>). Ferrostatin-1 administration significantly reduced the LV chamber size and improved cardiac function in TAC-operated mice. Pressure overload-induced increases in LV mass and weight, the cross-sectional area of cardiomyocytes, and remodeling markers such as <italic>Nppa</italic>, <italic>Nppb,</italic> and <italic>Myh7</italic> mRNAs were significantly attenuated in ferrostatin-1-treated hearts (<xref ref-type="fig" rid="fig6">Figure 6C and D</xref> and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>). TAC-operated saline-treated mice exhibited cardiac fibrosis, which was diminished by ferrostatin-1 (<xref ref-type="fig" rid="fig6">Figure 6D</xref> and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>). Thus, ferrostatin-1 prevented the development of pressure overload-induced cardiomyopathy. TAC-operated control mice showed increased lipid ROS and <italic>Ptgs2</italic> mRNA, which was inhibited by the administration of ferrostatin-1 (<xref ref-type="fig" rid="fig6">Figure 6E and F</xref> and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B</xref>). Taken together, these findings indicate that iron-dependent necrosis was involved in the pathogenesis of pressure overload-induced heart failure in the wild-type mice.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Inhibition of lipid peroxidation protects hearts from pressure overload.</title><p>Wild-type C57BL/6J mice were subjected to transverse aortic constriction (TAC) and analyzed 4 weeks after the operation. Ferrostatin-1 (Fer-1) or saline was intraperitoneally administered daily starting 1 day before TAC. (<bold>A</bold>) Representative images of transthoracic M-mode echocardiographic tracing. Scale bars, 0.1 s and 2 mm, respectively. (<bold>B</bold>) Echocardiographic parameters of the mice (<italic>n</italic> = 10 biologically independent samples). (<bold>C</bold>) Physiological parameters of the mice (<italic>n</italic> = 10 biologically independent samples). (<bold>D</bold>) Histological analysis of the heart. Scale bar, 50 μm. The upper and lower right graphs show the ratio of the fibrotic area to whole heart section and the cross-sectional area of cardiomyocytes, respectively (<italic>n</italic> = 5 biologically independent samples). (<bold>E</bold>) Cardiac MDA levels (<italic>n</italic> = 5 biologically independent samples). (<bold>F</bold>) <italic>Ptgs2</italic> mRNA levels in the hearts (<italic>n</italic> = 8 biologically independent samples). The data were evaluated by one-way analysis of variance (ANOVA) followed by Tukey–Kramer’s post hoc test. <sup>*</sup>p&lt;0.05, <sup>**</sup>p&lt;0.001, <sup>***</sup>p&lt;0.0001. NS, p&gt;0.05. Exact p-values are provided in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig6">Figure 6</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-62174-fig6-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62174-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Cardiac remodeling markers and 4-HNE staining in ferrostatin-1-treated transverse aortic constriction (TAC)-operated wild-type hearts.</title><p>The wild-type C57BL/6J mice were subjected to TAC. Ferrostatin-1 (Fer-1) was intraperitoneally administered daily starting one day before TAC. (<bold>A</bold>) The levels of mRNA were analyzed 4 weeks after the operation (<italic>n</italic> = 8 biologically independent samples). <italic>Gapdh</italic> mRNA was used as the loading control. (<bold>B</bold>) 4-Hydroxy-2-noneal (4-HNE) staining of heart sections. Scale bar, 50 μm. The right panel shows the quantitative analysis of 4-HNE-positive area (<italic>n</italic> = 5 biologically independent samples). The values are presented as the mean ± SEM. The data were evaluated by one-way analysis of variance (ANOVA) followed by Tukey–Kramer’s post hoc test. <sup>*</sup>p&lt;0.05, <sup>**</sup>p&lt;0.001, <sup>***</sup>p&lt;0.0001. NS, p&gt;0.05. Exact p-values are provided in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p><p><supplementary-material id="fig6s1sdata1"><label>Figure 6—figure supplement 1—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-62174-fig6-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62174-fig6-figsupp1-v1.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 2.</label><caption><title>Ferrostatin-1 does not provide additional protection from cardiac remodeling in <italic>Ncoa4</italic><sup>–/–</sup> mice.</title><p>The <italic>Ncoa4</italic><sup>–/–</sup> mice were subjected to TAC. Ferrostatin-1 (Fer-1) or saline was intraperitoneally administered daily starting one day before TAC. (<bold>A</bold>) Echocardiographic parameters of the mice (<italic>n</italic> = 5 biologically independent samples). LVIDd and LVIDs, end-diastolic and end-systolic left ventricular (LV) internal dimensions; IVSd, end-diastolic interventricular septum thickness; LVPWd, end-diastolic LV posterior wall thickness; FS, fractional shortening. (<bold>B</bold>) Physiological parameters of the mice (<italic>n</italic> = 5 biologically independent samples). The values are presented as the mean ± SEM. The data were evaluated by unpaired, two-tailed Student’s <italic>t</italic>-test. NS, p&gt;0.05. Exact <italic>P</italic> p-values are provided in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p><p><supplementary-material id="fig6s2sdata1"><label>Figure 6—figure supplement 2—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-62174-fig6-figsupp2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62174-fig6-figsupp2-v1.tif"/></fig></fig-group><p>To examine whether iron-dependent cell death is downstream of NCOA4, <italic>Ncoa4</italic><sup>–/–</sup> mice received an intraperitoneal daily injection of ferrostatin-1. Four weeks after TAC, there was no significant difference in the extent of cardiac remodeling between saline- and ferrostatin-1-treated mice (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2</xref>).</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Our data indicate that there is no cardiomyocyte-autonomous requirement for NCOA4 during normal embryonic development. Furthermore, the NCOA4-mediated pathway does not appear to be required for normal heart growth in the postnatal period. We found that NCOA4-dependent ferritinophagy is activated for degradation of ferritin in the heart in response to pressure overload and is detrimental in the stressed heart. The release of ferrous iron from ferritin leads to the increase in lipid ROS, cardiac necrosis, and heart failure.</p><p>We observed the reduction of FTH1 protein level in <italic>Ncoa4</italic><sup>+/+</sup> hearts 4 weeks after TAC as we previously reported (<xref ref-type="bibr" rid="bib27">Omiya et al., 2009</xref>). Because the mRNA level of FTH1 was also decreased, it was not conclusive that the decrease in FTH1 was due to increased ferritinophagy. Our study analyzing the heart during an earlier time course after pressure overload showed that the protein level of FTH1 decreased along with an increase in the level of <italic>Fth1</italic> mRNA, suggesting that the downregulation of FTH1 is due to its degradation. In the TAC-operated hearts, FTH1 was recruited in autophagosomes or autolysosomes and this recruitment was NCOA4-dependent. These findings confirmed that pressure overload induces the activation of NCOA4-mediated ferritinophagy, which is detrimental to the heart. The labile iron pool and oxidative stress are known to increase <italic>Fth1</italic> mRNA (<xref ref-type="bibr" rid="bib4">Arosio et al., 2009</xref>), which may explain the increased level of <italic>Fth1</italic> mRNA at the early time points after pressure overload. The detrimental effect of FTH1 downregulation on cardiac function is supported by a recent report showing that mice lacking FTH1 in cardiomyocytes increased oxidative stress, resulting in mild cardiac dysfunction upon aging (<xref ref-type="bibr" rid="bib10">Fang et al., 2020</xref>).</p><p>Iron is essential for the survival of the cells, as it serves as a cofactor in the biochemical processes such as oxygen storage, oxidative phosphorylation, and enzymatic reaction (<xref ref-type="bibr" rid="bib2">Andrews and Schmidt, 2007</xref>). Intracellular iron levels are maintained by NCOA4-dependent ferritin degradation (<xref ref-type="bibr" rid="bib21">Mancias et al., 2014</xref>). While ferritin supplies iron for mitochondrial function (<xref ref-type="bibr" rid="bib12">Fujimaki et al., 2019</xref>), it protects the cell against free radical generation via the Fenton reaction (<xref ref-type="bibr" rid="bib30">Papanikolaou and Pantopoulos, 2005</xref>). These suggest the importance of NCOA4 in intracellular iron homeostasis and a double-edged sword role of ferritinophagy. Our study presented here indicate that NCOA4-mediated ferritinophagy is pathologic for the heart in response to pressure overload by activating iron-dependent cell death. In addition, <italic>Ncoa4</italic><sup>–/–</sup> mice showed normal cardiac function at baseline as well as under hemodynamic stress, suggesting that iron derived from ferritin degradation is not necessary for cardiac homeostasis or some other transit pools of iron such as low-molecular-weight chelates including citrate, ATP, AMP, or pyrophosphate may compensate the loss of NCOA4 in the heart (<xref ref-type="bibr" rid="bib30">Papanikolaou and Pantopoulos, 2005</xref>). Why does the maladaptive hyperactivation of ferritinophagy occur in pressure overloaded hearts? NCOA4-dependent ferritinophagy is regulated by intracellular iron (<xref ref-type="bibr" rid="bib8">Dowdle et al., 2014</xref>; <xref ref-type="bibr" rid="bib21">Mancias et al., 2014</xref>). However, the precise activation mechanism of ferritinophagy–cell death pathway in response to hemodynamic stress remains to be elucidated. We found that β<sub>1</sub>-adrenergic agonist, isoproterenol, induced cardiomyocyte death in which the NCOA4-dependent pathway, the generation of lipid ROS, and increased labile iron pool are involved. In addition, we showed that isoproterenol induces ferritinophagy. Thus, the downstream signaling pathways of β<sub>1</sub>-adrenergic receptors activate ferritinophagy and resultant cell death. Another possibility is that isoproterenol induces intracellular iron deficiency in cardiomyocytes to lead to ferritinophagy. However, the expression level of FTH1 was maintained in cardiomyocyte-specific IREB1/2-deficient hearts with iron deficiency (<xref ref-type="bibr" rid="bib15">Haddad et al., 2016</xref>), suggesting that iron deficiency may not directly induce FTH1 degradation in cardiomyocytes. It is also possible that NCOA4 may associate with NRF2/HO-1 and VDACs-induced mitochondrial dysfunction pathways in ferroptosis-induced cardiomyocytes death and heart failure (<xref ref-type="bibr" rid="bib19">Li et al., 2020</xref>). It has been reported that NCOA4 has association with mitochondria iron-overload in cardiomyocyte hypertrophy pathophysiology (<xref ref-type="bibr" rid="bib35">Tang et al., 2019</xref>). Although NCOA4-mediated ferritin degradation contributes to maintain mitochondrial function through iron supply (<xref ref-type="bibr" rid="bib12">Fujimaki et al., 2019</xref>), excessive ferritinophagy may induce cardiomyocyte hypertrophy and cell death. Further studies are necessary to elucidate molecular mechanism underlying NCOA4-mediated cardiomyocyte death and heart failure.</p><p>Although pressure overload decreased the level of ferrous iron in the heart, the level of ferrous iron in <italic>Ncoa4</italic><sup>+/+</sup> hearts was higher than that in <italic>Ncoa4</italic><sup>–/–</sup> hearts. The calculated non-binding fraction of ferrous iron to FTH1 was higher in TAC-operated <italic>Ncoa4</italic><sup>+/+</sup> hearts. To confirm the increased level of ferrous iron in pressure overloaded <italic>Ncoa4</italic><sup>+/+</sup> hearts, we measured the labile iron pool in isolated cardiomyocytes. Erastin and isoproterenol could both increase the level of the labile iron pool in <italic>Ncoa4</italic><sup>+/+</sup> cardiomyocytes, which was attenuated by <italic>Ncoa4</italic> ablation. These suggest labile iron overload induced by activation of ferritinophagy in stressed cardiomyocytes, even though the pressure-overloaded <italic>Ncoa4</italic><sup>+/+</sup> mice exhibited decreased total cardiac iron.</p><p>Deregulation of programmed cardiomyocyte death has been reported to play an important role in the pathogenesis of heart failure (<xref ref-type="bibr" rid="bib37">Whelan et al., 2010</xref>). While apoptosis is the best-studied form of programmed cell death, there are also non-apoptotic programmed cell death. Necroptosis and iron-dependent necrosis are two distinct regulated necrotic cell death. We observed increases in lipid peroxidation in TAC-operated <italic>Ncoa4</italic><sup>+/+</sup> hearts but not in <italic>Ncoa4</italic><sup>–/–</sup> hearts. In addition, ferrostatin-1 attenuated the development of pressure overload-induced cardiac remodeling. Taken together, these results show that iron-dependent necrosis plays an important role in the development of pressure overload-induced heart failure. Ferrostatin-1 did not provide additional protection from pressure overload-induced cardiac remodeling in <italic>Ncoa4</italic><sup>–/–</sup> mice, suggesting that iron-dependent cardiomyocyte death is downstream of NCOA4-mediated ferritinophagy. GPX4 inhibits the formation of lipid peroxidation and ferroptosis (<xref ref-type="bibr" rid="bib38">Yang et al., 2014</xref>), while glutaminolyis is required for the execution of ferroptosis. We found that <italic>Ptgs2</italic> mRNA, a putative marker for ferroptosis, was upregulated TAC-operated <italic>Ncoa4</italic><sup>+/+</sup> hearts; however, the GPX4 protein level was upregulated, while glutamate and glutamine were downregulated in TAC-operated <italic>Ncoa4</italic><sup>+/+</sup> hearts. The mRNA of <italic>Slc7a11</italic> in system Xc<sup>–</sup> and cystine showed no difference between TAC-operated <italic>Ncoa4</italic><sup>+/+</sup> and <italic>Ncoa4</italic><sup>–/–</sup> hearts. These results suggest that the pressure overload-induced increase in GPX4 was compensatory to prevent iron-dependent necrosis, and insufficient induction of GPX4 may lead to the increase in lipid ROS and the downregulation of glutamine or glutamate was also a compensatory mechanism to inhibit iron-dependent necrosis. ROS have a variety of physiological and pathological functions depending on their source, species and local concentration, local antioxidant environment, and possibly the disease stage (<xref ref-type="bibr" rid="bib29">Papaharalambus and Griendling, 2007</xref>). Intensive studies have implicated ROS in the development of cardiovascular pathology including cardiac remodeling (<xref ref-type="bibr" rid="bib31">Ponikowski et al., 2016</xref>). However, the failure of clinical trials using antioxidants requests more precise understanding of the sources and contribution of ROS in heart failure. Our study indicates that lipid ROS derived from ferritinophagy and the Fenton reaction plays an important role in the pathogenesis of heart failure. Thus, our study supports the notion that inhibiting lipid peroxidation is cardioprotective during pressure overload.</p><p>Iron deficiency is a common condition affecting approximately 50% of patients with heart failure (<xref ref-type="bibr" rid="bib18">Lavoie, 2020</xref>). Clinical trials have demonstrated the symptomatic benefit of treating iron-deficient heart failure patients with intravenous iron supplementation (<xref ref-type="bibr" rid="bib3">Anker et al., 2009</xref>; <xref ref-type="bibr" rid="bib14">Ghafourian et al., 2020</xref>). However, heart failure patients may have underlying myocardial iron overload (<xref ref-type="bibr" rid="bib14">Ghafourian et al., 2020</xref>; <xref ref-type="bibr" rid="bib32">Sawicki et al., 2015</xref>). In addition, a high-iron diet caused severe cardiac dysfunction in cardiomyocyte-specific FTH1-deficient mice (<xref ref-type="bibr" rid="bib10">Fang et al., 2020</xref>). These raises concerns about the safety of the prolonged use of iron supplementation in heart failure patients. The long-term safety of iron supplementation in heart failure patients must be determined. Our results do not contradict the clinical trials but rather imply a potential role for reducing iron-dependent cell death in patients with heart failure.</p><p>In summary, the data presented here reveal a novel mechanism underlying the pathogenesis of heart failure. Iron-dependent cardiomyocyte death plays an important role in the development of pressure overload-induced heart failure. The inhibition of iron-dependent cardiomyocyte death can be a novel therapeutic mechanism for patients with heart failure.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th>Reagent type <break/>(species) or resource</th><th>Designation</th><th>Source or reference</th><th>Identifiers</th><th>Additional information</th></tr></thead><tbody><tr><td>Strain, strain background (male <italic>Mus musculus</italic>)</td><td>C57BL/6J</td><td>Envigo <break/>UK</td><td/><td>C57BL/6OlaHsd</td></tr><tr><td>Strain, strain background (male <italic>Mus musculus</italic>)</td><td><italic>Ncoa4</italic><sup>flox/flox</sup>;Myh6-Cre<sup>+</sup></td><td>This paper</td><td/><td>See Materials and methods</td></tr><tr><td>Strain, strain background (male <italic>Mus musculus</italic>)</td><td><italic>Ncoa4</italic><sup>flox/flox</sup>;Myh6-Cre<sup>–</sup></td><td>This paper</td><td/><td>See Materials and methods</td></tr><tr><td>Strain, strain background (male <italic>Mus musculus</italic>)</td><td>Myh6-Cre<sup>+</sup></td><td><xref ref-type="bibr" rid="bib25">Nishida et al., 2004</xref></td><td/><td>See Materials and methods</td></tr><tr><td>Antibody</td><td>Mouse monoclonal antibody to NCOA4</td><td>Sigma-Aldrich</td><td>SAB1404569, Lot: HC071-1F11, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10759525">AB_10759525</ext-link></td><td>(1:1000)</td></tr><tr><td>Antibody</td><td>Rabbit polyclonal antibody to FTH1</td><td>Cell Signaling Technology</td><td>3998, Lot: 2, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1903974">AB_1903974</ext-link></td><td>for western blots, (1:1000); for immunofluorescence, (1:100)</td></tr><tr><td>Antibody</td><td>Mouse monoclonal antibody to LC3B</td><td>Cell Signaling Technology</td><td>83506, Lot: 1, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2800018">AB_2800018</ext-link></td><td>(1:100)</td></tr><tr><td>Antibody</td><td>Rat monoclonal antibody to LAMP2a</td><td>Abcam</td><td>ab13524, Lot: GR3317907-1, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2134736">AB_2134736</ext-link></td><td>(1:100)</td></tr><tr><td>Antibody</td><td>Rat monoclonal antibody to GPX4</td><td>Millipore</td><td>MABS1274, Lot: Q2633070, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2885039">AB_2885039</ext-link></td><td>(1:1000)</td></tr><tr><td>Antibody</td><td>Rabbit polyclonal antibody to 4-HNE</td><td>Millipore</td><td>393207, Lot: 3167038, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_566310">AB_566310</ext-link></td><td>(1:500)</td></tr><tr><td>Antibody</td><td>Rabbit polyclonal antibody to IREB2</td><td>Thermo Fisher Scientific</td><td>PA1-16543, Lot: TK2666362A, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2126583">AB_2126583</ext-link></td><td>(1:250)</td></tr><tr><td>Antibody</td><td>Rabbit polyclonal antibody to SLC40A1</td><td>Alpha Diagnostic International</td><td>MTP11-A, Lot: 1169899A3-L, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1619475">AB_1619475</ext-link></td><td>(1:1000)</td></tr><tr><td>Antibody</td><td>Mouse monoclonal antibody to TFRC</td><td>Thermo Fisher Scientific</td><td>13–6800, Lot: TI275369, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2533029">AB_2533029</ext-link></td><td>(1:1000)</td></tr><tr><td>Antibody</td><td>Rabbit polyclonal antibody to SOD2</td><td>Abcam</td><td>ab13534, Lot: GR33618-66, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2191667">AB_2191667</ext-link></td><td>(1:1000)</td></tr><tr><td>Antibody</td><td>Rabbit polyclonal antibody to HO-1</td><td>Enzo Life Sciences</td><td>ADI-SPA-895, Lot: 03301708, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10618757">AB_10618757</ext-link></td><td>(1:1000)</td></tr><tr><td>Antibody</td><td>Mouse monoclonal antibody to GAPDH</td><td>Sigma-Aldrich</td><td>G8795, Lot: 056M4856V, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1078991">AB_1078991</ext-link></td><td>(1:10000)</td></tr><tr><td>Antibody</td><td>Mouse immunoglobulin</td><td>Santa Cruz biochemistry</td><td>sc-2025, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_737182">AB_737182</ext-link></td><td/></tr><tr><td>Antibody</td><td>Rabbit IgG</td><td>Abcam</td><td>ab37415, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2631996">AB_2631996</ext-link></td><td/></tr><tr><td>Antibody</td><td>Fluorescein isothiocyanate-conjugated lectin</td><td>Sigma-Aldrich</td><td>L4895</td><td/></tr><tr><td>Antibody</td><td>Alexa Fluor 488 donkey-anti-mouse</td><td>Thermo Fisher Scientific</td><td>A21202, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_141607">AB_141607</ext-link></td><td>(1:500)</td></tr><tr><td>Antibody</td><td>Alexa Fluor 568 donkey-anti-rabbit</td><td>Thermo Fisher Scientific</td><td>A10042, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2534017">AB_2534017</ext-link></td><td>(1:500)</td></tr><tr><td>Antibody</td><td>Alexa Fluor 488 goat-anti-rat</td><td>Thermo Fisher Scientific</td><td>A11006, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2534074">AB_2534074</ext-link></td><td>(1:500)</td></tr><tr><td>Antibody</td><td>IRDye 680LT Donkey anti-Mouse IgG Secondary Antibody</td><td>LI-COR Biosciences</td><td>926–68020, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10706161">AB_10706161</ext-link></td><td>(1:10,000)</td></tr><tr><td>Antibody</td><td>IRDye 680LT Donkey anti-Rabbit IgG Secondary Antibody</td><td>LI-COR Biosciences</td><td>926–68023, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10706167">AB_10706167</ext-link></td><td>(1:10,000)</td></tr><tr><td>Antibody</td><td>IRDye 680LT Goat anti-Rat IgG Secondary Antibody</td><td>LI-COR Biosciences</td><td>926–68029, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10715073">AB_10715073</ext-link></td><td>(1:10,000)</td></tr><tr><td>Commercial assay or kit</td><td>Pierce Protein G Magnetic Beads</td><td>Thermo Scientific</td><td>88848</td><td/></tr><tr><td>Commercial assay or kit</td><td>RNeasy Fibrous Tissue Mini Kit</td><td>QIAGEN</td><td>74704</td><td/></tr><tr><td>Commercial assay or kit</td><td>SuperScript IV First-Strand Synthesis System</td><td>Thermo Fisher Scientific</td><td>18091050</td><td/></tr><tr><td>Commercial assay or kit</td><td>PowerUp SYBR Green Master Mix</td><td>Thermo Fisher Scientific</td><td>A25742</td><td/></tr><tr><td>Commercial assay or kit</td><td>Masson's Trichrome Stain Kit</td><td>Polysciences, Inc</td><td>25088–1</td><td/></tr><tr><td>Commercial assay or kit</td><td>VECTASTAIN Elite ABC-HRP Kit, Peroxidase (Rabbit IgG)</td><td>Vector Laboratories Inc</td><td>PK-6101</td><td/></tr><tr><td>Commercial assay or kit</td><td>DAB Substrate Kit, Peroxidase (HRP), with Nickel, (3,3'-diaminobenzidine)</td><td>Vector Laboratories Inc</td><td>SK-4100</td><td/></tr><tr><td>Commercial assay or kit</td><td>normal donkey serum</td><td>Abcam</td><td>ab7475, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2885042">AB_2885042</ext-link></td><td/></tr><tr><td>Commercial assay or kit</td><td>normal goat serum</td><td>Abcam</td><td>ab7481, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2716553">AB_2716553</ext-link></td><td/></tr><tr><td>Commercial assay or kit</td><td>ProLong Gold Antifade Reagent with DAPI</td><td>Life Technologies</td><td>P36935</td><td/></tr><tr><td>Commercial assay or kit</td><td>Mouse Ferritin ELISA Kit (FTL)</td><td>Abcam</td><td>ab157713</td><td/></tr><tr><td>Commercial assay or kit</td><td>Pointe Scientific Iron/TIBC Reagents</td><td>Pointe Scientific</td><td>23-666-320</td><td/></tr><tr><td>Commercial assay or kit</td><td>ELISA Kit for Troponin T Type 2, Cardiac (TNNT2)</td><td>Cloud-Clone</td><td>SED232Mu</td><td/></tr><tr><td>Commercial assay or kit</td><td>Mouse IL-6 Quantikine ELISA Kit</td><td>R and D Systems</td><td>M6000B</td><td/></tr><tr><td>Commercial assay or kit</td><td>Iron Assay Kit</td><td>Abcam</td><td>ab83366</td><td/></tr><tr><td>Commercial assay or kit</td><td>Lipid Peroxidation (MDA) Assay Kit</td><td>Abcam</td><td>ab118970</td><td/></tr><tr><td>Commercial assay or kit</td><td>GSSG/GSH Quantification Kit</td><td>Dojindo</td><td>G257</td><td/></tr><tr><td>Commercial assay or kit</td><td>Glutamine Assay Kit</td><td>Abcam</td><td>ab197011</td><td/></tr><tr><td>Commercial assay or kit</td><td>Glutamate Assay Kit</td><td>Abcam</td><td>ab83389</td><td/></tr><tr><td>Commercial assay or kit</td><td>Electrophoretic Mobility-Shift Assay (EMSA) Kit</td><td>Invitrogen</td><td>E33075</td><td/></tr><tr><td>Commercial assay or kit</td><td>Zero Blunt TOPO PCR Cloning Kit</td><td>Invitrogen</td><td>451245</td><td/></tr><tr><td>Commercial assay or kit</td><td>HiScribe T7 Quick High Yield RNA Synthesis Kit</td><td>New England Biolabs</td><td>E2050S</td><td/></tr><tr><td>Chemical compound, drug</td><td>Ferrostatin-1</td><td>Sigma Aldrich</td><td>SML0583</td><td/></tr><tr><td>Chemical compound, drug</td><td>Isoprenaline hydrochloride</td><td>Sigma Aldrich</td><td>I5627</td><td/></tr><tr><td>Chemical compound, drug</td><td>Erastin</td><td>Sigma Aldrich</td><td>E7781</td><td/></tr><tr><td>Chemical compound, drug</td><td>1S,3R-RSL 3</td><td>Sigma Aldrich</td><td>SML2234</td><td/></tr><tr><td>Chemical compound, drug</td><td>calcein-AM</td><td>Invitrogen</td><td>C1430</td><td/></tr><tr><td>Chemical compound, drug</td><td>ethidium homodimer-1</td><td>Invitrogen</td><td>E1169</td><td/></tr><tr><td>Chemical compound, drug</td><td>2’, 7’-dichlorodihydrofluorescein diacetate (H2DCFDA)</td><td>Invitrogen</td><td>D399</td><td/></tr><tr><td>Chemical compound, drug</td><td>C11-BODIPY</td><td>Invitrogen</td><td>D3861</td><td/></tr><tr><td>Chemical compound, drug</td><td>pyridoxal isonicotinoyl hydrazine (PIH)</td><td>Abcam</td><td>ab145871</td><td/></tr><tr><td>Software, algorithm</td><td>ImageJ</td><td>National Institutes of Health</td><td>Version 1.51 r, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_003070">SCR_003070</ext-link></td><td/></tr><tr><td>Software, algorithm</td><td>GraphPad Prism 8</td><td>GraphPad Software</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_002798">SCR_002798</ext-link></td><td/></tr><tr><td>Software, algorithm</td><td>EZChrom Elite</td><td>Agilent Technologies</td><td>Version 3.3.2.</td><td/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Animal studies</title><p>All procedures were carried out in accordance with the King’s College London Ethical Review Process Committee and the UK Home Office (Project License No. PPL70/8889) and were performed in accordance with the Guidance on the Operation of the Animals (Scientific Procedures) Act, 1986 (UK Home Office).</p></sec><sec id="s4-2"><title>Antibodies</title><p>The following antibodies were used in this study: monoclonal mouse antibody to NCOA4 (Sigma-Aldrich, SAB1404569, Lot: HC071-1F11, 1/1000), polyclonal rabbit antibody to FTH1 (Cell Signaling Technology, 3998, Lot: 2, for western blots, 1/1000; for immunofluorescence, 1/100), monoclonal mouse antibody to LC3B (Cell Signaling Technology: 83506, Lot: 1, 1/100), monoclonal rat antibody to LAMP2a (Abcam: ab13524, Lot: GR3317907-1, 1/100), monoclonal rat antibody to GPX4 (Millipore: MABS1274, Lot: Q2633070, 1/1000), polyclonal rabbit antibody to 4-HNE (Millipore: 393207, Lot: 3167038, 1/500), polyclonal rabbit antibody to IREB2 (Thermo Fisher Scientific: PA1-16543, Lot: TK2666362A, 1/250), polyclonal rabbit antibody to SLC40A1 (Alpha Diagnostic International: MTP11-A, Lot: 1169899A3-L, 1/1000), monoclonal mouse antibody to TFRC (Thermo Fisher Scientific: 13–6800, Lot: TI275369, 1/1000), polyclonal rabbit antibody to SOD2 (Abcam: ab13534, Lot: GR33618-66, 1/1000), polyclonal rabbit antibody to HO-1 (Enzo Life Sciences: ADI-SPA-895, Lot: 03301708, 1/1000), monoclonal mouse antibody to GAPDH (Sigma-Aldrich: G8795, Lot: 056M4856V, 1/10,000).</p></sec><sec id="s4-3"><title>Generation of cardiomyocyte-specific NCOA4-deficient mice</title><p>The <italic>Ncoa4</italic> gene-targeting vector was constructed using mouse C57BL/6J genomic DNA (<xref ref-type="bibr" rid="bib24">Misaka et al., 2018</xref>). The targeting vector was electroporated into ES cells (F1; SVJ129 and C57BL/6J), and the transfected ES clones were selected for neomycin resistance according to standard protocols. The neomycin-resistant ES clones with targeted homologous recombination were screened by PCR and further confirmed by Southern blotting. Circular pCAG-Flpe plasmid and pPGK-Puro plasmid were electroporated into the selected ES clones, and the transfected ES clones were selected for puromycin resistance according to standard protocols. The neomycin cassette-excised ES clones were screened by PCR. Southern blotting and karyotyping analyses were performed to obtain ES clones exhibiting the desired homologous recombination and normal karyotype. These targeted ES clones were injected into blastocyst C57BL/6J mouse embryos to generate chimeric mice. The chimeric mice were crossed with C57BL/6J mice to validate germ line transmission. We generated mice with the floxed <italic>Ncoa4</italic> allele and crossed them with transgenic mice expressing α-myosin heavy chain promoter-driven Cre recombinase (Myh6-Cre) to obtain cardiomyocyte-specific NCOA4-deficient mice (<italic>Ncoa4</italic><sup>flox/flox</sup>;Myh6-Cre<sup>+</sup>) (<xref ref-type="bibr" rid="bib25">Nishida et al., 2004</xref>). <italic>Ncoa4</italic><sup>flox/flox</sup>;Myh6-Cre<sup>–</sup> littermates were used as controls. The mice had access to food and water ad libitum.</p></sec><sec id="s4-4"><title>Immunoprecipitation and western blot analysis</title><p>To evaluate NCOA4 protein expression level in hearts, the protein was immunoprecipitated with an anti-NCOA4 antibody, followed by immunoblot with the antibody. One hundred micrograms protein homogenates with lysis buffer (50 mmol/L Tris-HCl, 50 mmol/L NaCl, 1 mmol/L EDTA, 1% NP-40, a protease inhibitor cocktail, pH 7.4) were precleared with 20 μL of magnetic beads-coupled protein G (Thermo Fisher Scientific, 1004D). Precleared homogenates were subjected to immunoprecipitation using 1 μg of the anti-NCOA4 antibody (Sigma-Aldrich, SAB1404569) or mouse immunoglobulin G (IgG; Santa Cruz biochemistry, sc-2025) and 40 μL of magnetic beads-coupled protein G at 4 °C for 2 hr. The precipitated complexes were washed three times with lysis buffer. Protein homogenates with lysis buffer were extracted from the left ventricles. The precipitated complexes or 5–15 μg of total protein homogenates were subjected to western blot analysis. After incubation with secondary antibody, the blot was developed with an infrared imaging system (ODYSSEY CLx; LI-COR Biosciences). Image Studio software (LI-COR Biosciences) was used for quantitative analysis to evaluate protein expression levels.</p></sec><sec id="s4-5"><title>Real-time quantitative reverse transcription PCR</title><p>Total RNA was isolated from the left ventricles using RNeasy Fibrous Tissue Mini Kit (QIAGEN). The mRNA expression levels were determined by quantitative reverse transcription polymerase chain reaction (PCR) using SuperScript IV reverse transcriptase (Thermo Fisher Scientific Inc) for reverse transcription and a PowerUp SYBR Green PCR Master Mix (Thermo Fisher Scientific) for the quantitative PCR reaction with the following PCR primers: forward 5’-<named-content content-type="sequence">CTATATCCAGGTGCCAGAGCAG-</named-content>3’ and reverse 5’-<named-content content-type="sequence">TTGCTTACAAGAAGCCACTCAC-</named-content>3’ for <italic>Ncoa4</italic>, forward 5’-<named-content content-type="sequence">TGGAGTTGTATGCCTCCTACG-</named-content>3’ and reverse 5’-<named-content content-type="sequence">TGGAGAAAGTATTTGGCAAAGTT-</named-content>3’ for <italic>Fth1</italic>, forward 5’-<named-content content-type="sequence">CAGACAACATAAACTGCGCCTT-</named-content>3’ and reverse 5’-<named-content content-type="sequence">GATACACCTCTCCACCAATGACC-</named-content>3’ for <italic>Ptgs2</italic>, forward 5’-<named-content content-type="sequence">TGGCCAGCAAGATTGTGGAGAT-</named-content>3’ and reverse 5’-<named-content content-type="sequence">TTTGCGGGTGAAGAGGAAGT-</named-content>3’ for <italic>Slc1a5</italic>, forward 5’-<named-content content-type="sequence">ATGGAGTGTGGCATTGGCTT-</named-content>3’ and reverse 5’-<named-content content-type="sequence">TGCATCAGCTTCTGGCAGAGCA-</named-content>3’ for <italic>Slc7a5</italic>, forward 5’-<named-content content-type="sequence">TCTACAGGATTGCGAACATCT-</named-content>3’ and reverse 5’-<named-content content-type="sequence">CTTTGTCTAGCATGACACCATCT-</named-content>3’ for <italic>Gls1</italic>, forward 5’-<named-content content-type="sequence">AGCGTATCCCTATCCACAAGTTCA-</named-content>3’ and reverse 5’-<named-content content-type="sequence">GCAGTCCAGTGGCCTTCAGAG-</named-content>3’ for <italic>Gls2</italic>, forward 5’-<named-content content-type="sequence">TCGTCTTGGCCTTTTGGCT</named-content>–3’ and reverse 5’-<named-content content-type="sequence">TCCAGGTGGTCTAGCAGGTTCT-</named-content>3’ for <italic>Nppa</italic>, forward 5’-<named-content content-type="sequence">AAGTCCTAGCCAGTCTCCAGA-</named-content>3’ and reverse 5’-<named-content content-type="sequence">GAGCTGTCTCTGGGCCATTTC-</named-content>3’ for <italic>Nppb</italic>, forward 5’-<named-content content-type="sequence">ATGTGCCGGACCTTGGAAG-</named-content>3’ and reverse 5’-<named-content content-type="sequence">CCTCGGGTTAGCTGAGAGATCA-</named-content>3’ for <italic>Myh7</italic>, forward 5’-<named-content content-type="sequence">ACGCGGACTCTGTTGCTGCT-</named-content>3’ and reverse 5’-<named-content content-type="sequence">GCGGGACCCCTTTGTCCACG-</named-content>3’ for <italic>Col1a2</italic>, forward 5’-<named-content content-type="sequence">CCCGGGTGCTCCTGGACAGA-</named-content>3’ and reverse 5’-<named-content content-type="sequence">CACCCTGAGGACCAGGCGGA-</named-content>3’ for <italic>Col3a1</italic>, forward 5’-<named-content content-type="sequence">TGCAATCTGCATCTCCATGGCT-</named-content>3’ and reverse 5’-<named-content content-type="sequence">AAGCAGGAGAGGGCAACAAA-</named-content>3’ for <italic>Slc7a11</italic>, forward 5’-<named-content content-type="sequence">TGGAATCCCAGCAGTTTCTT-</named-content>3’ and reverse 5’-<named-content content-type="sequence">GCTGCTGTACGAACCATTTG-</named-content>3’ for <italic>Tfrc</italic>, forward 5’-<named-content content-type="sequence">GGCTTTCTTATGAGCATTGCCTA-</named-content>3’ and reverse 5’-<named-content content-type="sequence">GGAGCACCCAGAGCAGCTTA-</named-content>3’ for Slc11a2, forward 5’-<named-content content-type="sequence">TGGACCTCTGAACTTGGCAAT-</named-content>3’ and reverse 5’-<named-content content-type="sequence">AGATGACGGCATAAGCACCTAT-</named-content>3’ for <italic>Cdc14a</italic>, forward 5’-<named-content content-type="sequence">TTTCCACCTAAGCGCAAGACT-</named-content>3’ and reverse 5’-<named-content content-type="sequence">ATGACATGAGAACCCACAGA-</named-content>3’ for <italic>Cdc42bpa</italic>, and forward 5’-<named-content content-type="sequence">ATGACAACTTTGTCAAGCTCATTT-</named-content>3’ and reverse 5’-<named-content content-type="sequence">GGTCCACCACCCTGTTGCT-</named-content>3’ for <italic>Gapdh</italic>. PCR standard curves were constructed using the corresponding cDNA and all data were normalized to the <italic>Gapdh</italic> mRNA content and are expressed as the fold increase over the control group.</p></sec><sec id="s4-6"><title>Transverse aortic constriction (TAC) and echocardiography</title><p>The 8– to 12 week-old male mice were subjected to TAC using a 26-gauge needle or to a sham surgery, as previously reported (<xref ref-type="bibr" rid="bib28">Omiya et al., 2020</xref>). In TAC, a small piece of 6–0 silk suture was placed between the innominate and left carotid arteries. Three loose knots were tied around the transverse aorta, and a 26-gauge needle was placed parallel to the transverse aorta. The knots were tied quickly against the needle and the needle was removed promptly to yield a 26-gauge stenosis. Sham surgeries were identical except for the aortic constriction. Echocardiography was conducted with a Vevo 2100 system (Visual Sonics) on conscious mice (<xref ref-type="bibr" rid="bib28">Omiya et al., 2020</xref>). Noninvasive measurement of the tail blood pressure was also performed on conscious mice using a NP-NIBP Monitor for mice and rats (Muromachi Kikai), as previously described (<xref ref-type="bibr" rid="bib28">Omiya et al., 2020</xref>).</p></sec><sec id="s4-7"><title>Histological analysis</title><p>Left ventricle samples were embedded in OCT compound (Thermo Fisher Scientific Inc) and then immediately frozen in liquid nitrogen. The samples were sectioned into 5 μm thick sections. The sections were fixed with acetone for hematoxylin–eosin staining and Masson’s trichrome staining, with 4% paraformaldehyde for wheat germ agglutinin staining and with Bouin’s solution for 4-HNE staining. Hematoxylin–eosin staining and Masson’s trichrome staining (Masson’s Trichrome Stain Kit, Polysciences Inc) were performed on serial sections. For wheat germ agglutinin staining, heart samples were stained with fluorescein isothiocyanate-conjugated lectin (Sigma, L4895) to measure the cross-sectional area of cardiomyocytes. For 4-HNE staining, rabbit anti-4-HNE antibody or control rabbit IgG (Abcam, ab37415) were used as primary antibody, and avidin-peroxidase (Vectastain Elite ABC Kit; Vector Laboratories Inc) and the DAB Peroxidase Substrate Kit (Vector Laboratories Inc) were applied, followed by counterstaining with hematoxylin as described previously (<xref ref-type="bibr" rid="bib28">Omiya et al., 2020</xref>). Images were captured by an All-in-one fluorescence microscope (BZ-X700, Keyence). Quantitative analyses of the fibrosis fraction and 4-HNE positive area were examined in whole left ventricles and cardiomyocyte cross-sectional areas we examined in five different areas per section and measured using ImageJ (National Institutes of Health; Version 1.51 r).</p></sec><sec id="s4-8"><title>Immunofluorescence microscopy</title><p>The OCT-compound embedded frozen left ventricle samples were used to detect LC3B-FTH1 and LAMP2a-FTH1 co-localization dots. The samples were sectioned into 5 μm thick sections and fixed with 4% paraformaldehyde for immunohistochemical fluorescence staining. The samples were blocked with 10% normal donkey serum (Abcam, ab7475) to detect LC3B-FTH1 co-localization and with 10% normal donkey serum and 10% normal goat serum (Abcam, ab7481) to detect LAMP2a-FTH1 co-localization. The primary antibodies were rabbit anti-FTH1, mouse anti-LC3B, and rat anti-LAMP2a. The secondary antibodies were Alexa Fluor 488 donkey-anti-mouse (Thermo Fisher Scientific: A21202, 1/500), Alexa Fluor 568 donkey-anti-rabbit (Thermo Fisher Scientific: A10042, 1/500), and Alexa Fluor 488 goat-anti-rat (Thermo Fisher Scientific: A11006, 1/500). DAPI (ProLong Gold Antifade Reagent with DAPI; Life Technologies: P36935) was used to detect nuclei. Micrographs were acquired using a Nikon Eclipse Ti inverted microscope (Nikon) equipped with a Yokogawa CSU-X1 spinning disk unit (Yokagawa) and an Andor EMMCD camera (Andor Technology) using a 100x oil immersion objective lens. The co-localization dots were quantified by counting the number of LC3B-FTH1- or LAMP2a-FTH1-positive dots in 10 different areas (magnification 1000x) per section.</p></sec><sec id="s4-9"><title>Measurement of hematological parameters, serum ferritin, serum iron, transferrin saturation, serum troponin T, and serum IL-6</title><p>Blood samples were obtained from the inferior vena cava in anesthetized mice. Full blood count and reticulocyte count were measured at Pinmoore Animal Laboratory Services Limited. Blood samples were centrifuged for 30 min at 850 x g to isolate serum fraction. Serum ferritin levels were measured using a Mouse Ferritin ELISA Kit (FTL) (Abcam, ab157713) according to the manufacturer’s protocols. Serum iron levels and transferrin saturation were measured using Pointe Scientific Iron/TIBC Reagents (Pointe Scientific, 23-666-320) according to the manufacturer’s protocols. Serum troponin T levels were measured using the ELISA Kit for Troponin T Type 2, Cardiac (TNNT2) (Cloud-Clone, SED232Mu) according to the manufacturer’s protocols. Serum IL-6 levels were measured using the ELISA Kit for Mouse IL-6 (R and D Systems, M6000B) according to the manufacturer’s protocols.</p></sec><sec id="s4-10"><title>Measurement of total non-heme, ferrous, and ferric iron levels in hearts</title><p>Total non-heme, ferrous, and ferric iron in hearts or liver were analyzed using an Iron Assay Kit (Abcam, ab83366) according to the manufacturer’s protocols. Briefly, the whole heart was perfused with saline and 10–20 mg of left ventricle tissue was homogenized in Iron Assay Buffer. The supernatant without the insoluble fraction was separated by centrifugation and used for analysis. A microplate reader was used to measure the absorbance at OD 593 nm. The level of ferric iron was calculated by subtracting ferrous iron from total non-heme iron. The ratio of the ferrous iron level to the FTH1 protein level was calculated to estimate non-binding fraction of ferrous iron to FTH1. The FTH1 protein level for sham-operated <italic>Ncoa4</italic><sup>+/+</sup> estimated as Western blot analysis in hearts was set to 1.</p></sec><sec id="s4-11"><title>Measurement of malondialdehyde (MDA) in hearts</title><p>The amount of MDA in the hearts was measured using a Lipid Peroxidation (MDA) Assay Kit (Abcam, ab118970) according to the manufacturer’s protocols. Briefly, 10–20 mg of fresh left ventricle tissue was homogenized in Lysis Solution containing butylated hydroxytoluene. The insoluble fraction was removed by centrifugation, and the supernatant was used for analysis. The supernatants were mixed with thiobarbituric acid (TBA) solution reconstituted in glacial acetic acid and then incubated at 95°C for 60 min. The supernatants containing MDA-TBA adduct were added into a 96-well microplate for analysis. A microplate reader was used to measure the absorbance at OD 532 nm.</p></sec><sec id="s4-12"><title>Glutathione quantification</title><p>Oxidized glutathione (GSSG) and total glutathione in hearts were analyzed using a GSSG/GSH Quantification Kit (Dojindo, G257) according to the manufacturer’s protocols. Briefly, 20–30 mg of fresh left ventricle tissue was homogenized in 5% 5-sulfosalicylic acid (SSA), and the insoluble fraction was removed by centrifugation. The resultant supernatant was added to double-deionized H<sub>2</sub>O (ddH<sub>2</sub>O) to reduce the SSA concentration to 0.5% for the assay. A microplate reader was used to measure absorbance at OD 415 nm. The concentration of reduced glutathione (GSH) was calculated by subtracting 2x GSSG from the total glutathione concentration.</p></sec><sec id="s4-13"><title>Measurement of glutamine and glutamate concentration in hearts</title><p>The glutamine concentration in hearts was analyzed using a Glutamine Assay Kit (Abcam, ab197011) according to the manufacturer’s protocols. Briefly, 10–20 mg of fresh left ventricle tissue was homogenized in ice-cold Hydrolysis Buffer, and the insoluble fraction was removed by centrifugation. The supernatant was added to perchloric acid (PCA). After 5 minutes incubation on ice, the samples were centrifuged and the supernatants were transferred into new tubes. To remove excess PCA, potassium hydroxide was added to the supernatant and the precipitated PCA was removed by centrifugation. A microplate reader was used to measure the absorbance at OD 450 nm. The glutamate concentration in hearts was analyzed using a Glutamate Assay Kit (Abcam, ab83389) according to the manufacturer’s protocols. Briefly, 10–20 mg of fresh left ventricle tissue was homogenized in ice-cold Assay Buffer, and the insoluble fraction was removed by centrifugation. The supernatants were added into a 96-well microplate for analysis. A microplate reader was used to measure the absorbance at OD 450 nm.</p></sec><sec id="s4-14"><title>Free amino acid analysis by high–performance liquid chromatography (HPLC)</title><p>The mouse hearts were grinded with liquid nitrogen. Proteins were precipitated out from the mouse hearts using a 5% SSA solution, filtered and then measured by ion exchange chromatography with post column ninhydrin derivatization using a Biochrom 30+ amino acid analyzer with a lithium buffer system (Biochrom). EZChrom Elite software (Version 3.3.2.) was used for analysis.</p></sec><sec id="s4-15"><title>Electrophoretic mobility–shift assay (EMSA)</title><p>Electrophoretic mobility–shift assay (EMSA) was performed using Electrophoretic Mobility-Shift Assay kit (Invitrogen: E33075), according to the manufacturer's instructions. The following IRE containing mouse <italic>Slc40a1</italic> 5’ UTR with T7 promoter was synthesized by Integrated DNA Technologies (gBlocks Gene Fragments): 5’-<named-content content-type="sequence">TAATACGACTCACTATAGGGGAGAGCAGGCTCGGGGTCTCCTGCGGCCGGTGGATCCTCCAACCCGCTCCCATAAGGCTTTGGCTTTCCAACTTCAGCTACAGTGTTAGCTAAGTTTGGAAAGAAGACAAAAAGAAGACCCCGTGACAGCTTTGCTGTTGTTGTTTGCCTTAGTTGTCCTTTGGGGTCTTTCGGCATAAGGCTGTTGTGCTTATACTGGTGCTATCTTCGGTTCCTCTCACTCCTGTGAACAAGCTCCCGGGCAAGAGCAGCTAAAGCTACCAGCAT-</named-content>3’. The 287 bp fragment was cloned into pCR-Blunt II-TOPO (Invitrogen: 451245). This plasmid DNA containing the mouse <italic>Slc40a1</italic> 5’ UTR was linearized by EcoRI and transcribed using HiScrib T7 Quick High Yield RNA Synthesis Kit (New England Biolabs: E2050S). Twenty micrograms of total protein homogenates from mouse heart were incubated with 50 ng of RNA oligonucleotides and subjected to electrophoresis on 6% nondenaturing polyacrylamide gels. The gels were stained using SYBR Green EMSA stain and captured using ChemiDoc-It Imaging Systems with Transilluminator (UVP).</p></sec><sec id="s4-16"><title>Isolation of mouse adult cardiomyocytes</title><p>Adult cardiomyocytes were isolated from 8- to 12-week-old male mice using a Langendorff system and cultured (<xref ref-type="bibr" rid="bib26">Oka et al., 2012</xref>). Briefly, after <italic>Ncoa4<sup>+/</sup></italic><sup>+</sup> or <italic>Ncoa4</italic><sup>–/–</sup> male mice had been deeply anesthetized, the heart was quickly excised, cannulated via the aorta, and perfused at constant flow. Hearts were first perfused for 1 minute at 37°C with a perfusion buffer containing 120 mM NaCl, 5.4 mM KCl, 1.6 mM MgCl<sub>2</sub>, 1.2 mM NaH<sub>2</sub>PO<sub>4</sub>, 5.6 mM glucose, 20 mM NaHCO<sub>3</sub> and 5 mM taurine (Sigma-Aldrich), followed by collagenase buffer containing 1.2 mg/ml collagenase type 2 (Worthington Biochemical Corporation), and 0.016 mg/ml protease type XIV (Sigma-Aldrich: P-5147). After collagenase and protease digestion, the supernatant containing the dispersed myocytes was filtered into a sterilized tube and gently centrifuged at 20 x g for 3 minutes. The cell pellet was then promptly resuspended in perfusion buffer containing 200 μM Ca<sup>2+</sup>. The cardiomyocytes were pelleted by gravity for 10 min, the supernatant was aspirated, and the cardiomyocytes were resuspended in perfusion buffer containing 500 µM Ca<sup>2+</sup>. The final cell pellet was suspended in perfusion buffer containing 1 mM Ca<sup>2+</sup>, and an appropriate amount of rod-shaped cardiomyocytes was then suspended in Minimum Essential Medium Eagle (MEM) (Sigma-Aldrich: M5650) supplemented with 2.5% fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin, and 100 g/ml streptomycin (Sigma-Aldrich: G6784) and plated onto laminin (Invitrogen: 23017–015)-coated plates. After one hour of incubation in the culture medium, the cardiomyocytes were cultured in MEM (glutamine- and phenol red-free, Gibco: 51200038) supplemented with 1x MEM non-essential amino acids solution (Gibco: 11140035), 100 µg/ml bovine serum albumin, insulin (10 mg/l)-transferrin (5.5 mg/l)-sodium selenite (6.7 μg/l) media supplement (ITS; Gibco: 41400045), 2 mM L-glutamine, 100 U/ml penicillin, and 100 g/ml streptomycin (Sigma-Aldrich: G6784).</p></sec><sec id="s4-17"><title>Cell death and ROS production</title><p>Cardiomyocyte death was estimated using a Live/Dead Viability/Cytotoxicity Assay Kit (Invitrogen). Isolated adult cardiomyocytes were pre-treated with or without 10 μM ferrostatin-1 (Sigma Aldrich: SML0583) for 30 min before treatment with 10 or 20 μM erastin (Sigma Aldrich: E7781), 10 or 100 μM isoproterenol (Sigma Aldrich: I5627), or 2 or 5 μM RSL3 (Sigma Aldrich: SML2234). The cells were then stimulated with or without ferrostatin-1 in the medium for four hours. After stimulation, the cells were stained with 1 mM calcein-AM (Invitrogen: C1430) and 2 μM ethidium homodimer-1 (Invitrogen: E1169) in the medium at 37°C for 10 min. The cells were washed three times using the medium and observed under a microscope (BZ-X700, Keyence). ROS production was measured by applying several indicators. After treatment with erastin or isoproterenol with or without ferrostatin-1, cells were stained with 25 μM 2’, 7’-dichlorodihydrofluorescein diacetate (H2DCFDA; Invitrogen: D399) or C11-BODIPY (Invitrogen: D3861) in medium at 37°C for 10 min. The cells were then washed with the medium. ROS production was quantified using a fluorescence microplate reader.</p></sec><sec id="s4-18"><title>Measurement of the labile iron pool</title><p>The labile iron pool in the isolated adult cardiomyocytes was measured by the calcein-AM method (<xref ref-type="bibr" rid="bib39">Yoshida et al., 2019</xref>). After treatment with indicated concentration of erastin or isoproterenol with or without 30 min treatment of 10 μM ferrostatin-1, cells were incubated with 1 μM calcein-AM at 37°C for 10 min and then washed three times with the medium. The fluorescence was measured using a fluorescence microplate reader. Then, the cells were treated with 10 μM pyridoxal isonicotinoyl hydrazine (PIH; Abcam: ab145871) at 37°C for 10 min, and washed three times with the medium. The fluorescence was measured again in a fluorescence microplate reader. The changes in fluorescence (ΔF) upon PIH treatment was calculated for each sample.</p></sec><sec id="s4-19"><title>Administration of ferrostatin-1</title><p>Twenty-five mg of ferrostatin-1 was dissolved in 2.5 mL of DMSO, and then diluted with saline to the intended concentration. The final DMSO concentration was 5%. One day before and after TAC operation, the C57BL/6J mice or <italic>Ncoa4</italic><sup>flox/flox</sup>;Myh6-Cre<sup>+</sup> mice received an intraperitoneal injection of one mg/kg body weight ferrostatin-1 or saline containing 5% DMSO and every day thereafter. Following saline or ferrostain-1 injection, the mice were randomly assigned into sham and TAC groups.</p></sec><sec id="s4-20"><title>Statistics</title><p>The results are shown as the mean ± SEM. Statistical analyses were performed using GraphPad Prism 8 (GraphPad Software). Paired data were evaluated by unpaired, two-tailed Student’s <italic>t</italic>-test. A one-way analysis of variance (ANOVA) followed by Tukey–Kramer’s post hoc test was used for multiple comparisons. A two-way ANOVA followed by Tukey's multiple comparisons test was used for the in vitro experiments. p&lt;0.05 was considered to be statistically significant.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank Dr Erika Cadoni, Dr Saki Nakagawa, and Mr. Darran Hardy for their excellent technical assistance. We thank Dr George Chennell and Ms Chen Liang, the Wohl Cellular Imaging Centre at King’s College London, for help with spinning disk confocal microscopy. This work was supported by grants from the British Heart Foundation (CH/11/3/29051 and RG/16/15/32294), the Fondation Leducq (RA15CVD04), the European Research Council (692659), Japan Society for the Promotion of Science KAKENHI (18H02807), and Osaka University (International Joint Research Promotion Program) to K Otsu and from the British Heart Foundation to AM Shah (CH/1999001/11735 and RE/13/2/30182).</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Software, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Data curation, Supervision, Validation, Investigation, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Data curation, Formal analysis, Validation, Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con5"><p>Data curation, Formal analysis, Validation, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con6"><p>Data curation, Formal analysis, Validation, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con7"><p>Data curation, Formal analysis, Validation, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con8"><p>Data curation, Formal analysis, Validation, Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con9"><p>Supervision, Writing - review and editing</p></fn><fn fn-type="con" id="con10"><p>Data curation, Formal analysis, Supervision, Validation, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Resources, Software, Formal analysis, Supervision, Validation, Investigation, Visualization, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con12"><p>Resources, Funding acquisition, Validation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con13"><p>Conceptualization, Supervision, Funding acquisition, Validation, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All procedures were carried out in accordance with the King's College London Ethical Review Process Committee and the UK Home Office (Project License No. PPL70/8889) and were performed in accordance with the Guidance on the Operation of the Animals (Scientific Procedures) Act, 1986 (UK Home Office).</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Quantification and statistical analysis.</title><p>The number of independent biological repeats (<italic>n</italic>) is shown in the figure legends. <italic>P</italic> values are shown below.</p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-62174-supp1-v1.docx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-62174-transrepform-v1.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated or analyzed during this study are included in the manuscript and supporting files.</p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname> <given-names>CP</given-names></name><name><surname>Shen</surname> <given-names>M</given-names></name><name><surname>Eisenstein</surname> <given-names>RS</given-names></name><name><surname>Leibold</surname> <given-names>EA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Mammalian iron metabolism and its control by iron regulatory proteins</article-title><source>Biochimica Et Biophysica Acta (BBA) - Molecular Cell Research</source><volume>1823</volume><fpage>1468</fpage><lpage>1483</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2012.05.010</pub-id><pub-id pub-id-type="pmid">22610083</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andrews</surname> <given-names>NC</given-names></name><name><surname>Schmidt</surname> <given-names>PJ</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Iron homeostasis</article-title><source>Annual Review of Physiology</source><volume>69</volume><fpage>69</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1146/annurev.physiol.69.031905.164337</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anker</surname> <given-names>SD</given-names></name><name><surname>Comin Colet</surname> <given-names>J</given-names></name><name><surname>Filippatos</surname> <given-names>G</given-names></name><name><surname>Willenheimer</surname> <given-names>R</given-names></name><name><surname>Dickstein</surname> <given-names>K</given-names></name><name><surname>Drexler</surname> <given-names>H</given-names></name><name><surname>Lüscher</surname> <given-names>TF</given-names></name><name><surname>Bart</surname> <given-names>B</given-names></name><name><surname>Banasiak</surname> <given-names>W</given-names></name><name><surname>Niegowska</surname> <given-names>J</given-names></name><name><surname>Kirwan</surname> <given-names>B-A</given-names></name><name><surname>Mori</surname> <given-names>C</given-names></name><name><surname>von Eisenhart Rothe</surname> <given-names>B</given-names></name><name><surname>Pocock</surname> <given-names>SJ</given-names></name><name><surname>Poole-Wilson</surname> <given-names>PA</given-names></name><name><surname>Ponikowski</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Ferric Carboxymaltose in patients with heart failure and iron deficiency</article-title><source>New England Journal of Medicine</source><volume>361</volume><fpage>2436</fpage><lpage>2448</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0908355</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arosio</surname> <given-names>P</given-names></name><name><surname>Ingrassia</surname> <given-names>R</given-names></name><name><surname>Cavadini</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Ferritins: a family of molecules for iron storage, antioxidation and more</article-title><source>Biochimica Et Biophysica Acta (BBA) - General Subjects</source><volume>1790</volume><fpage>589</fpage><lpage>599</lpage><pub-id pub-id-type="doi">10.1016/j.bbagen.2008.09.004</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ayala</surname> <given-names>A</given-names></name><name><surname>Muñoz</surname> <given-names>MF</given-names></name><name><surname>Argüelles</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-Hydroxy-2-Nonenal</article-title><source>Oxidative Medicine and Cellular Longevity</source><volume>2014</volume><fpage>1</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1155/2014/360438</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bellelli</surname> <given-names>R</given-names></name><name><surname>Federico</surname> <given-names>G</given-names></name><name><surname>Matte'</surname> <given-names>A</given-names></name><name><surname>Colecchia</surname> <given-names>D</given-names></name><name><surname>Iolascon</surname> <given-names>A</given-names></name><name><surname>Chiariello</surname> <given-names>M</given-names></name><name><surname>Santoro</surname> <given-names>M</given-names></name><name><surname>De Franceschi</surname> <given-names>L</given-names></name><name><surname>Carlomagno</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>NCOA4 deficiency impairs systemic iron homeostasis</article-title><source>Cell Reports</source><volume>14</volume><fpage>411</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2015.12.065</pub-id><pub-id pub-id-type="pmid">26776506</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dixon</surname> <given-names>SJ</given-names></name><name><surname>Lemberg</surname> <given-names>KM</given-names></name><name><surname>Lamprecht</surname> <given-names>MR</given-names></name><name><surname>Skouta</surname> <given-names>R</given-names></name><name><surname>Zaitsev</surname> <given-names>EM</given-names></name><name><surname>Gleason</surname> <given-names>CE</given-names></name><name><surname>Patel</surname> <given-names>DN</given-names></name><name><surname>Bauer</surname> <given-names>AJ</given-names></name><name><surname>Cantley</surname> <given-names>AM</given-names></name><name><surname>Yang</surname> <given-names>WS</given-names></name><name><surname>Morrison</surname> <given-names>B</given-names></name><name><surname>Stockwell</surname> <given-names>BR</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Ferroptosis: an iron-dependent form of nonapoptotic cell death</article-title><source>Cell</source><volume>149</volume><fpage>1060</fpage><lpage>1072</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.03.042</pub-id><pub-id pub-id-type="pmid">22632970</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dowdle</surname> <given-names>WE</given-names></name><name><surname>Nyfeler</surname> <given-names>B</given-names></name><name><surname>Nagel</surname> <given-names>J</given-names></name><name><surname>Elling</surname> <given-names>RA</given-names></name><name><surname>Liu</surname> <given-names>S</given-names></name><name><surname>Triantafellow</surname> <given-names>E</given-names></name><name><surname>Menon</surname> <given-names>S</given-names></name><name><surname>Wang</surname> <given-names>Z</given-names></name><name><surname>Honda</surname> <given-names>A</given-names></name><name><surname>Pardee</surname> <given-names>G</given-names></name><name><surname>Cantwell</surname> <given-names>J</given-names></name><name><surname>Luu</surname> <given-names>C</given-names></name><name><surname>Cornella-Taracido</surname> <given-names>I</given-names></name><name><surname>Harrington</surname> <given-names>E</given-names></name><name><surname>Fekkes</surname> <given-names>P</given-names></name><name><surname>Lei</surname> <given-names>H</given-names></name><name><surname>Fang</surname> <given-names>Q</given-names></name><name><surname>Digan</surname> <given-names>ME</given-names></name><name><surname>Burdick</surname> <given-names>D</given-names></name><name><surname>Powers</surname> <given-names>AF</given-names></name><name><surname>Helliwell</surname> <given-names>SB</given-names></name><name><surname>D'Aquin</surname> <given-names>S</given-names></name><name><surname>Bastien</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>H</given-names></name><name><surname>Wiederschain</surname> <given-names>D</given-names></name><name><surname>Kuerth</surname> <given-names>J</given-names></name><name><surname>Bergman</surname> <given-names>P</given-names></name><name><surname>Schwalb</surname> <given-names>D</given-names></name><name><surname>Thomas</surname> <given-names>J</given-names></name><name><surname>Ugwonali</surname> <given-names>S</given-names></name><name><surname>Harbinski</surname> <given-names>F</given-names></name><name><surname>Tallarico</surname> <given-names>J</given-names></name><name><surname>Wilson</surname> <given-names>CJ</given-names></name><name><surname>Myer</surname> <given-names>VE</given-names></name><name><surname>Porter</surname> <given-names>JA</given-names></name><name><surname>Bussiere</surname> <given-names>DE</given-names></name><name><surname>Finan</surname> <given-names>PM</given-names></name><name><surname>Labow</surname> <given-names>MA</given-names></name><name><surname>Mao</surname> <given-names>X</given-names></name><name><surname>Hamann</surname> <given-names>LG</given-names></name><name><surname>Manning</surname> <given-names>BD</given-names></name><name><surname>Valdez</surname> <given-names>RA</given-names></name><name><surname>Nicholson</surname> <given-names>T</given-names></name><name><surname>Schirle</surname> <given-names>M</given-names></name><name><surname>Knapp</surname> <given-names>MS</given-names></name><name><surname>Keaney</surname> <given-names>EP</given-names></name><name><surname>Murphy</surname> <given-names>LO</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Selective VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in ferritin degradation and iron homeostasis in vivo</article-title><source>Nature Cell Biology</source><volume>16</volume><fpage>1069</fpage><lpage>1079</lpage><pub-id pub-id-type="doi">10.1038/ncb3053</pub-id><pub-id pub-id-type="pmid">25327288</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname> <given-names>X</given-names></name><name><surname>Wang</surname> <given-names>H</given-names></name><name><surname>Han</surname> <given-names>D</given-names></name><name><surname>Xie</surname> <given-names>E</given-names></name><name><surname>Yang</surname> <given-names>X</given-names></name><name><surname>Wei</surname> <given-names>J</given-names></name><name><surname>Gu</surname> <given-names>S</given-names></name><name><surname>Gao</surname> <given-names>F</given-names></name><name><surname>Zhu</surname> <given-names>N</given-names></name><name><surname>Yin</surname> <given-names>X</given-names></name><name><surname>Cheng</surname> <given-names>Q</given-names></name><name><surname>Zhang</surname> <given-names>P</given-names></name><name><surname>Dai</surname> <given-names>W</given-names></name><name><surname>Chen</surname> <given-names>J</given-names></name><name><surname>Yang</surname> <given-names>F</given-names></name><name><surname>Yang</surname> <given-names>HT</given-names></name><name><surname>Linkermann</surname> <given-names>A</given-names></name><name><surname>Gu</surname> <given-names>W</given-names></name><name><surname>Min</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Ferroptosis as a target for protection against cardiomyopathy</article-title><source>PNAS</source><volume>116</volume><fpage>2672</fpage><lpage>2680</lpage><pub-id pub-id-type="doi">10.1073/pnas.1821022116</pub-id><pub-id pub-id-type="pmid">30692261</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname> <given-names>X</given-names></name><name><surname>Cai</surname> <given-names>Z</given-names></name><name><surname>Wang</surname> <given-names>H</given-names></name><name><surname>Han</surname> <given-names>D</given-names></name><name><surname>Cheng</surname> <given-names>Q</given-names></name><name><surname>Zhang</surname> <given-names>P</given-names></name><name><surname>Gao</surname> <given-names>F</given-names></name><name><surname>Yu</surname> <given-names>Y</given-names></name><name><surname>Song</surname> <given-names>Z</given-names></name><name><surname>Wu</surname> <given-names>Q</given-names></name><name><surname>An</surname> <given-names>P</given-names></name><name><surname>Huang</surname> <given-names>S</given-names></name><name><surname>Pan</surname> <given-names>J</given-names></name><name><surname>Chen</surname> <given-names>HZ</given-names></name><name><surname>Chen</surname> <given-names>J</given-names></name><name><surname>Linkermann</surname> <given-names>A</given-names></name><name><surname>Min</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Loss of cardiac ferritin H facilitates cardiomyopathy via Slc7a11-Mediated ferroptosis</article-title><source>Circulation Research</source><volume>127</volume><fpage>486</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.120.316509</pub-id><pub-id pub-id-type="pmid">32349646</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedmann Angeli</surname> <given-names>JP</given-names></name><name><surname>Schneider</surname> <given-names>M</given-names></name><name><surname>Proneth</surname> <given-names>B</given-names></name><name><surname>Tyurina</surname> <given-names>YY</given-names></name><name><surname>Tyurin</surname> <given-names>VA</given-names></name><name><surname>Hammond</surname> <given-names>VJ</given-names></name><name><surname>Herbach</surname> <given-names>N</given-names></name><name><surname>Aichler</surname> <given-names>M</given-names></name><name><surname>Walch</surname> <given-names>A</given-names></name><name><surname>Eggenhofer</surname> <given-names>E</given-names></name><name><surname>Basavarajappa</surname> <given-names>D</given-names></name><name><surname>Rådmark</surname> <given-names>O</given-names></name><name><surname>Kobayashi</surname> <given-names>S</given-names></name><name><surname>Seibt</surname> <given-names>T</given-names></name><name><surname>Beck</surname> <given-names>H</given-names></name><name><surname>Neff</surname> <given-names>F</given-names></name><name><surname>Esposito</surname> <given-names>I</given-names></name><name><surname>Wanke</surname> <given-names>R</given-names></name><name><surname>Förster</surname> <given-names>H</given-names></name><name><surname>Yefremova</surname> <given-names>O</given-names></name><name><surname>Heinrichmeyer</surname> <given-names>M</given-names></name><name><surname>Bornkamm</surname> <given-names>GW</given-names></name><name><surname>Geissler</surname> <given-names>EK</given-names></name><name><surname>Thomas</surname> <given-names>SB</given-names></name><name><surname>Stockwell</surname> <given-names>BR</given-names></name><name><surname>O'Donnell</surname> <given-names>VB</given-names></name><name><surname>Kagan</surname> <given-names>VE</given-names></name><name><surname>Schick</surname> <given-names>JA</given-names></name><name><surname>Conrad</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice</article-title><source>Nature Cell Biology</source><volume>16</volume><fpage>1180</fpage><lpage>1191</lpage><pub-id pub-id-type="doi">10.1038/ncb3064</pub-id><pub-id pub-id-type="pmid">25402683</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujimaki</surname> <given-names>M</given-names></name><name><surname>Furuya</surname> <given-names>N</given-names></name><name><surname>Saiki</surname> <given-names>S</given-names></name><name><surname>Amo</surname> <given-names>T</given-names></name><name><surname>Imamichi</surname> <given-names>Y</given-names></name><name><surname>Hattori</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Iron supply via NCOA4-Mediated ferritin degradation maintains mitochondrial functions</article-title><source>Molecular and Cellular Biology</source><volume>39</volume><elocation-id>19</elocation-id><pub-id pub-id-type="doi">10.1128/MCB.00010-19</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname> <given-names>M</given-names></name><name><surname>Monian</surname> <given-names>P</given-names></name><name><surname>Quadri</surname> <given-names>N</given-names></name><name><surname>Ramasamy</surname> <given-names>R</given-names></name><name><surname>Jiang</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Glutaminolysis and transferrin regulate ferroptosis</article-title><source>Molecular Cell</source><volume>59</volume><fpage>298</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2015.06.011</pub-id><pub-id pub-id-type="pmid">26166707</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghafourian</surname> <given-names>K</given-names></name><name><surname>Shapiro</surname> <given-names>JS</given-names></name><name><surname>Goodman</surname> <given-names>L</given-names></name><name><surname>Ardehali</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Iron and heart failure: diagnosis, therapies, and future directions</article-title><source>JACC. Basic to Translational Science</source><volume>5</volume><fpage>300</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1016/j.jacbts.2019.08.009</pub-id><pub-id pub-id-type="pmid">32215351</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haddad</surname> <given-names>S</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Galy</surname> <given-names>B</given-names></name><name><surname>Korf-Klingebiel</surname> <given-names>M</given-names></name><name><surname>Hirsch</surname> <given-names>V</given-names></name><name><surname>Baru</surname> <given-names>AM</given-names></name><name><surname>Rostami</surname> <given-names>F</given-names></name><name><surname>Reboll</surname> <given-names>MR</given-names></name><name><surname>Heineke</surname> <given-names>J</given-names></name><name><surname>Flögel</surname> <given-names>U</given-names></name><name><surname>Groos</surname> <given-names>S</given-names></name><name><surname>Renner</surname> <given-names>A</given-names></name><name><surname>Toischer</surname> <given-names>K</given-names></name><name><surname>Zimmermann</surname> <given-names>F</given-names></name><name><surname>Engeli</surname> <given-names>S</given-names></name><name><surname>Jordan</surname> <given-names>J</given-names></name><name><surname>Bauersachs</surname> <given-names>J</given-names></name><name><surname>Hentze</surname> <given-names>MW</given-names></name><name><surname>Wollert</surname> <given-names>KC</given-names></name><name><surname>Kempf</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Iron-regulatory proteins secure iron availability in cardiomyocytes to prevent heart failure</article-title><source>European Heart Journal</source><volume>33</volume><elocation-id>ehw333</elocation-id><pub-id pub-id-type="doi">10.1093/eurheartj/ehw333</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirota</surname> <given-names>H</given-names></name><name><surname>Izumi</surname> <given-names>M</given-names></name><name><surname>Hamaguchi</surname> <given-names>T</given-names></name><name><surname>Sugiyama</surname> <given-names>S</given-names></name><name><surname>Murakami</surname> <given-names>E</given-names></name><name><surname>Kunisada</surname> <given-names>K</given-names></name><name><surname>Fujio</surname> <given-names>Y</given-names></name><name><surname>Oshima</surname> <given-names>Y</given-names></name><name><surname>Nakaoka</surname> <given-names>Y</given-names></name><name><surname>Yamauchi-Takihara</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Circulating interleukin-6 family cytokines and their receptors in patients with congestive heart failure</article-title><source>Heart and Vessels</source><volume>19</volume><fpage>237</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1007/s00380-004-0770-z</pub-id><pub-id pub-id-type="pmid">15372299</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kell</surname> <given-names>DB</given-names></name><name><surname>Pretorius</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells</article-title><source>Metallomics</source><volume>6</volume><fpage>748</fpage><lpage>773</lpage><pub-id pub-id-type="doi">10.1039/C3MT00347G</pub-id><pub-id pub-id-type="pmid">24549403</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lavoie</surname> <given-names>AJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Iron deficiency in heart failure: getting to the guidelines</article-title><source>Current Opinion in Cardiology</source><volume>35</volume><fpage>133</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1097/HCO.0000000000000714</pub-id><pub-id pub-id-type="pmid">31904605</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Cao</surname> <given-names>F</given-names></name><name><surname>Yin</surname> <given-names>HL</given-names></name><name><surname>Huang</surname> <given-names>ZJ</given-names></name><name><surname>Lin</surname> <given-names>ZT</given-names></name><name><surname>Mao</surname> <given-names>N</given-names></name><name><surname>Sun</surname> <given-names>B</given-names></name><name><surname>Wang</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Ferroptosis: past, present and future</article-title><source>Cell Death &amp; Disease</source><volume>11</volume><elocation-id>88</elocation-id><pub-id pub-id-type="doi">10.1038/s41419-020-2298-2</pub-id><pub-id pub-id-type="pmid">32015325</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linkermann</surname> <given-names>A</given-names></name><name><surname>Skouta</surname> <given-names>R</given-names></name><name><surname>Himmerkus</surname> <given-names>N</given-names></name><name><surname>Mulay</surname> <given-names>SR</given-names></name><name><surname>Dewitz</surname> <given-names>C</given-names></name><name><surname>De Zen</surname> <given-names>F</given-names></name><name><surname>Prokai</surname> <given-names>A</given-names></name><name><surname>Zuchtriegel</surname> <given-names>G</given-names></name><name><surname>Krombach</surname> <given-names>F</given-names></name><name><surname>Welz</surname> <given-names>PS</given-names></name><name><surname>Weinlich</surname> <given-names>R</given-names></name><name><surname>Vanden Berghe</surname> <given-names>T</given-names></name><name><surname>Vandenabeele</surname> <given-names>P</given-names></name><name><surname>Pasparakis</surname> <given-names>M</given-names></name><name><surname>Bleich</surname> <given-names>M</given-names></name><name><surname>Weinberg</surname> <given-names>JM</given-names></name><name><surname>Reichel</surname> <given-names>CA</given-names></name><name><surname>Bräsen</surname> <given-names>JH</given-names></name><name><surname>Kunzendorf</surname> <given-names>U</given-names></name><name><surname>Anders</surname> <given-names>HJ</given-names></name><name><surname>Stockwell</surname> <given-names>BR</given-names></name><name><surname>Green</surname> <given-names>DR</given-names></name><name><surname>Krautwald</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Synchronized renal tubular cell death involves ferroptosis</article-title><source>PNAS</source><volume>111</volume><fpage>16836</fpage><lpage>16841</lpage><pub-id pub-id-type="doi">10.1073/pnas.1415518111</pub-id><pub-id pub-id-type="pmid">25385600</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mancias</surname> <given-names>JD</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Gygi</surname> <given-names>SP</given-names></name><name><surname>Harper</surname> <given-names>JW</given-names></name><name><surname>Kimmelman</surname> <given-names>AC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy</article-title><source>Nature</source><volume>509</volume><fpage>105</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1038/nature13148</pub-id><pub-id pub-id-type="pmid">24695223</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGivan</surname> <given-names>JD</given-names></name><name><surname>Bungard</surname> <given-names>CI</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>The transport of glutamine into mammalian cells</article-title><source>Frontiers in Bioscience</source><volume>12</volume><fpage>874</fpage><lpage>882</lpage><pub-id pub-id-type="doi">10.2741/2109</pub-id><pub-id pub-id-type="pmid">17127344</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miotto</surname> <given-names>G</given-names></name><name><surname>Rossetto</surname> <given-names>M</given-names></name><name><surname>Di Paolo</surname> <given-names>ML</given-names></name><name><surname>Orian</surname> <given-names>L</given-names></name><name><surname>Venerando</surname> <given-names>R</given-names></name><name><surname>Roveri</surname> <given-names>A</given-names></name><name><surname>Vučković</surname> <given-names>AM</given-names></name><name><surname>Bosello Travain</surname> <given-names>V</given-names></name><name><surname>Zaccarin</surname> <given-names>M</given-names></name><name><surname>Zennaro</surname> <given-names>L</given-names></name><name><surname>Maiorino</surname> <given-names>M</given-names></name><name><surname>Toppo</surname> <given-names>S</given-names></name><name><surname>Ursini</surname> <given-names>F</given-names></name><name><surname>Cozza</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Insight into the mechanism of ferroptosis inhibition by ferrostatin-1</article-title><source>Redox Biology</source><volume>28</volume><elocation-id>101328</elocation-id><pub-id pub-id-type="doi">10.1016/j.redox.2019.101328</pub-id><pub-id pub-id-type="pmid">31574461</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Misaka</surname> <given-names>T</given-names></name><name><surname>Murakawa</surname> <given-names>T</given-names></name><name><surname>Nishida</surname> <given-names>K</given-names></name><name><surname>Omori</surname> <given-names>Y</given-names></name><name><surname>Taneike</surname> <given-names>M</given-names></name><name><surname>Omiya</surname> <given-names>S</given-names></name><name><surname>Molenaar</surname> <given-names>C</given-names></name><name><surname>Uno</surname> <given-names>Y</given-names></name><name><surname>Yamaguchi</surname> <given-names>O</given-names></name><name><surname>Takeda</surname> <given-names>J</given-names></name><name><surname>Shah</surname> <given-names>AM</given-names></name><name><surname>Otsu</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>FKBP8 protects the heart from hemodynamic stress by preventing the accumulation of misfolded proteins and endoplasmic reticulum-associated apoptosis in mice</article-title><source>Journal of Molecular and Cellular Cardiology</source><volume>114</volume><fpage>93</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1016/j.yjmcc.2017.11.004</pub-id><pub-id pub-id-type="pmid">29129702</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishida</surname> <given-names>K</given-names></name><name><surname>Yamaguchi</surname> <given-names>O</given-names></name><name><surname>Hirotani</surname> <given-names>S</given-names></name><name><surname>Hikoso</surname> <given-names>S</given-names></name><name><surname>Higuchi</surname> <given-names>Y</given-names></name><name><surname>Watanabe</surname> <given-names>T</given-names></name><name><surname>Takeda</surname> <given-names>T</given-names></name><name><surname>Osuka</surname> <given-names>S</given-names></name><name><surname>Morita</surname> <given-names>T</given-names></name><name><surname>Kondoh</surname> <given-names>G</given-names></name><name><surname>Uno</surname> <given-names>Y</given-names></name><name><surname>Kashiwase</surname> <given-names>K</given-names></name><name><surname>Taniike</surname> <given-names>M</given-names></name><name><surname>Nakai</surname> <given-names>A</given-names></name><name><surname>Matsumura</surname> <given-names>Y</given-names></name><name><surname>Miyazaki</surname> <given-names>J</given-names></name><name><surname>Sudo</surname> <given-names>T</given-names></name><name><surname>Hongo</surname> <given-names>K</given-names></name><name><surname>Kusakari</surname> <given-names>Y</given-names></name><name><surname>Kurihara</surname> <given-names>S</given-names></name><name><surname>Chien</surname> <given-names>KR</given-names></name><name><surname>Takeda</surname> <given-names>J</given-names></name><name><surname>Hori</surname> <given-names>M</given-names></name><name><surname>Otsu</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>p38alpha mitogen-activated protein kinase plays a critical role in cardiomyocyte survival but not in cardiac hypertrophic growth in response to pressure overload</article-title><source>Molecular and Cellular Biology</source><volume>24</volume><fpage>10611</fpage><lpage>10620</lpage><pub-id pub-id-type="doi">10.1128/MCB.24.24.10611-10620.2004</pub-id><pub-id pub-id-type="pmid">15572667</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oka</surname> <given-names>T</given-names></name><name><surname>Hikoso</surname> <given-names>S</given-names></name><name><surname>Yamaguchi</surname> <given-names>O</given-names></name><name><surname>Taneike</surname> <given-names>M</given-names></name><name><surname>Takeda</surname> <given-names>T</given-names></name><name><surname>Tamai</surname> <given-names>T</given-names></name><name><surname>Oyabu</surname> <given-names>J</given-names></name><name><surname>Murakawa</surname> <given-names>T</given-names></name><name><surname>Nakayama</surname> <given-names>H</given-names></name><name><surname>Nishida</surname> <given-names>K</given-names></name><name><surname>Akira</surname> <given-names>S</given-names></name><name><surname>Yamamoto</surname> <given-names>A</given-names></name><name><surname>Komuro</surname> <given-names>I</given-names></name><name><surname>Otsu</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure</article-title><source>Nature</source><volume>485</volume><fpage>251</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1038/nature10992</pub-id><pub-id pub-id-type="pmid">22535248</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Omiya</surname> <given-names>S</given-names></name><name><surname>Hikoso</surname> <given-names>S</given-names></name><name><surname>Imanishi</surname> <given-names>Y</given-names></name><name><surname>Saito</surname> <given-names>A</given-names></name><name><surname>Yamaguchi</surname> <given-names>O</given-names></name><name><surname>Takeda</surname> <given-names>T</given-names></name><name><surname>Mizote</surname> <given-names>I</given-names></name><name><surname>Oka</surname> <given-names>T</given-names></name><name><surname>Taneike</surname> <given-names>M</given-names></name><name><surname>Nakano</surname> <given-names>Y</given-names></name><name><surname>Matsumura</surname> <given-names>Y</given-names></name><name><surname>Nishida</surname> <given-names>K</given-names></name><name><surname>Sawa</surname> <given-names>Y</given-names></name><name><surname>Hori</surname> <given-names>M</given-names></name><name><surname>Otsu</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Downregulation of ferritin heavy chain increases labile iron pool, oxidative stress and cell death in cardiomyocytes </article-title><source>Journal of Molecular and Cellular Cardiology</source><volume>46</volume><fpage>59</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/j.yjmcc.2008.09.714</pub-id><pub-id pub-id-type="pmid">18992754</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Omiya</surname> <given-names>S</given-names></name><name><surname>Omori</surname> <given-names>Y</given-names></name><name><surname>Taneike</surname> <given-names>M</given-names></name><name><surname>Murakawa</surname> <given-names>T</given-names></name><name><surname>Ito</surname> <given-names>J</given-names></name><name><surname>Tanada</surname> <given-names>Y</given-names></name><name><surname>Nishida</surname> <given-names>K</given-names></name><name><surname>Yamaguchi</surname> <given-names>O</given-names></name><name><surname>Satoh</surname> <given-names>T</given-names></name><name><surname>Shah</surname> <given-names>AM</given-names></name><name><surname>Akira</surname> <given-names>S</given-names></name><name><surname>Otsu</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Cytokine mRNA degradation in cardiomyocytes restrains sterile inflammation in Pressure-Overloaded hearts</article-title><source>Circulation</source><volume>141</volume><fpage>667</fpage><lpage>677</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.119.044582</pub-id><pub-id pub-id-type="pmid">31931613</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papaharalambus</surname> <given-names>CA</given-names></name><name><surname>Griendling</surname> <given-names>KK</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Basic mechanisms of oxidative stress and reactive oxygen species in cardiovascular injury</article-title><source>Trends in Cardiovascular Medicine</source><volume>17</volume><fpage>48</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1016/j.tcm.2006.11.005</pub-id><pub-id pub-id-type="pmid">17292046</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papanikolaou</surname> <given-names>G</given-names></name><name><surname>Pantopoulos</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Iron metabolism and toxicity</article-title><source>Toxicology and Applied Pharmacology</source><volume>202</volume><fpage>199</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1016/j.taap.2004.06.021</pub-id><pub-id pub-id-type="pmid">15629195</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ponikowski</surname> <given-names>P</given-names></name><name><surname>Voors</surname> <given-names>AA</given-names></name><name><surname>Anker</surname> <given-names>SD</given-names></name><name><surname>Bueno</surname> <given-names>H</given-names></name><name><surname>Cleland</surname> <given-names>JGF</given-names></name><name><surname>Coats</surname> <given-names>AJS</given-names></name><name><surname>Falk</surname> <given-names>V</given-names></name><name><surname>González-Juanatey</surname> <given-names>JR</given-names></name><name><surname>Harjola</surname> <given-names>VP</given-names></name><name><surname>Jankowska</surname> <given-names>EA</given-names></name><name><surname>Jessup</surname> <given-names>M</given-names></name><name><surname>Linde</surname> <given-names>C</given-names></name><name><surname>Nihoyannopoulos</surname> <given-names>P</given-names></name><name><surname>Parissis</surname> <given-names>JT</given-names></name><name><surname>Pieske</surname> <given-names>B</given-names></name><name><surname>Riley</surname> <given-names>JP</given-names></name><name><surname>Rosano</surname> <given-names>GMC</given-names></name><name><surname>Ruilope</surname> <given-names>LM</given-names></name><name><surname>Ruschitzka</surname> <given-names>F</given-names></name><name><surname>Rutten</surname> <given-names>FH</given-names></name><name><surname>van der Meer</surname> <given-names>P</given-names></name><collab>ESC Scientific Document Group</collab></person-group><year iso-8601-date="2016">2016</year><article-title>2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the european society of cardiology (ESC)Developed with the special contribution of the heart failure association (HFA) of the ESC</article-title><source>European Heart Journal</source><volume>37</volume><fpage>2129</fpage><lpage>2200</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehw128</pub-id><pub-id pub-id-type="pmid">27206819</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sawicki</surname> <given-names>KT</given-names></name><name><surname>Shang</surname> <given-names>M</given-names></name><name><surname>Wu</surname> <given-names>R</given-names></name><name><surname>Chang</surname> <given-names>HC</given-names></name><name><surname>Khechaduri</surname> <given-names>A</given-names></name><name><surname>Sato</surname> <given-names>T</given-names></name><name><surname>Kamide</surname> <given-names>C</given-names></name><name><surname>Liu</surname> <given-names>T</given-names></name><name><surname>Naga Prasad</surname> <given-names>SV</given-names></name><name><surname>Ardehali</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Increased heme levels in the heart lead to exacerbated ischemic injury</article-title><source>Journal of the American Heart Association</source><volume>4</volume><elocation-id>e002272</elocation-id><pub-id pub-id-type="doi">10.1161/JAHA.115.002272</pub-id><pub-id pub-id-type="pmid">26231844</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname> <given-names>AM</given-names></name><name><surname>Mann</surname> <given-names>DL</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>In search of new therapeutic targets and strategies for heart failure: recent advances in basic science</article-title><source>The Lancet</source><volume>378</volume><fpage>704</fpage><lpage>712</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(11)60894-5</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skouta</surname> <given-names>R</given-names></name><name><surname>Dixon</surname> <given-names>SJ</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Dunn</surname> <given-names>DE</given-names></name><name><surname>Orman</surname> <given-names>M</given-names></name><name><surname>Shimada</surname> <given-names>K</given-names></name><name><surname>Rosenberg</surname> <given-names>PA</given-names></name><name><surname>Lo</surname> <given-names>DC</given-names></name><name><surname>Weinberg</surname> <given-names>JM</given-names></name><name><surname>Linkermann</surname> <given-names>A</given-names></name><name><surname>Stockwell</surname> <given-names>BR</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models</article-title><source>Journal of the American Chemical Society</source><volume>136</volume><fpage>4551</fpage><lpage>4556</lpage><pub-id pub-id-type="doi">10.1021/ja411006a</pub-id><pub-id pub-id-type="pmid">24592866</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname> <given-names>M</given-names></name><name><surname>Huang</surname> <given-names>Z</given-names></name><name><surname>Luo</surname> <given-names>X</given-names></name><name><surname>Liu</surname> <given-names>M</given-names></name><name><surname>Wang</surname> <given-names>L</given-names></name><name><surname>Qi</surname> <given-names>Z</given-names></name><name><surname>Huang</surname> <given-names>S</given-names></name><name><surname>Zhong</surname> <given-names>J</given-names></name><name><surname>Chen</surname> <given-names>JX</given-names></name><name><surname>Li</surname> <given-names>L</given-names></name><name><surname>Wu</surname> <given-names>D</given-names></name><name><surname>Chen</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Ferritinophagy activation and sideroflexin1-dependent mitochondria iron overload is involved in apelin-13-induced cardiomyocytes hypertrophy</article-title><source>Free Radical Biology and Medicine</source><volume>134</volume><fpage>445</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2019.01.052</pub-id><pub-id pub-id-type="pmid">30731113</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tuo</surname> <given-names>Q-z</given-names></name><name><surname>Lei</surname> <given-names>P</given-names></name><name><surname>Jackman</surname> <given-names>KA</given-names></name><name><surname>Li</surname> <given-names>X-l</given-names></name><name><surname>Xiong</surname> <given-names>H</given-names></name><name><surname>Li</surname> <given-names>X-l</given-names></name><name><surname>Liuyang</surname> <given-names>Z-y</given-names></name><name><surname>Roisman</surname> <given-names>L</given-names></name><name><surname>Zhang</surname> <given-names>S-t</given-names></name><name><surname>Ayton</surname> <given-names>S</given-names></name><name><surname>Wang</surname> <given-names>Q</given-names></name><name><surname>Crouch</surname> <given-names>PJ</given-names></name><name><surname>Ganio</surname> <given-names>K</given-names></name><name><surname>Wang</surname> <given-names>X-c</given-names></name><name><surname>Pei</surname> <given-names>L</given-names></name><name><surname>Adlard</surname> <given-names>PA</given-names></name><name><surname>Lu</surname> <given-names>Y-m</given-names></name><name><surname>Cappai</surname> <given-names>R</given-names></name><name><surname>Wang</surname> <given-names>J-z</given-names></name><name><surname>Liu</surname> <given-names>R</given-names></name><name><surname>Bush</surname> <given-names>AI</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Tau-mediated iron export prevents ferroptotic damage after ischemic stroke</article-title><source>Molecular Psychiatry</source><volume>22</volume><fpage>1520</fpage><lpage>1530</lpage><pub-id pub-id-type="doi">10.1038/mp.2017.171</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whelan</surname> <given-names>RS</given-names></name><name><surname>Kaplinskiy</surname> <given-names>V</given-names></name><name><surname>Kitsis</surname> <given-names>RN</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Cell death in the pathogenesis of heart disease: mechanisms and significance</article-title><source>Annual Review of Physiology</source><volume>72</volume><fpage>19</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1146/annurev.physiol.010908.163111</pub-id><pub-id pub-id-type="pmid">20148665</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>WS</given-names></name><name><surname>SriRamaratnam</surname> <given-names>R</given-names></name><name><surname>Welsch</surname> <given-names>ME</given-names></name><name><surname>Shimada</surname> <given-names>K</given-names></name><name><surname>Skouta</surname> <given-names>R</given-names></name><name><surname>Viswanathan</surname> <given-names>VS</given-names></name><name><surname>Cheah</surname> <given-names>JH</given-names></name><name><surname>Clemons</surname> <given-names>PA</given-names></name><name><surname>Shamji</surname> <given-names>AF</given-names></name><name><surname>Clish</surname> <given-names>CB</given-names></name><name><surname>Brown</surname> <given-names>LM</given-names></name><name><surname>Girotti</surname> <given-names>AW</given-names></name><name><surname>Cornish</surname> <given-names>VW</given-names></name><name><surname>Schreiber</surname> <given-names>SL</given-names></name><name><surname>Stockwell</surname> <given-names>BR</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Regulation of ferroptotic Cancer cell death by GPX4</article-title><source>Cell</source><volume>156</volume><fpage>317</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.12.010</pub-id><pub-id pub-id-type="pmid">24439385</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname> <given-names>M</given-names></name><name><surname>Minagawa</surname> <given-names>S</given-names></name><name><surname>Araya</surname> <given-names>J</given-names></name><name><surname>Sakamoto</surname> <given-names>T</given-names></name><name><surname>Hara</surname> <given-names>H</given-names></name><name><surname>Tsubouchi</surname> <given-names>K</given-names></name><name><surname>Hosaka</surname> <given-names>Y</given-names></name><name><surname>Ichikawa</surname> <given-names>A</given-names></name><name><surname>Saito</surname> <given-names>N</given-names></name><name><surname>Kadota</surname> <given-names>T</given-names></name><name><surname>Sato</surname> <given-names>N</given-names></name><name><surname>Kurita</surname> <given-names>Y</given-names></name><name><surname>Kobayashi</surname> <given-names>K</given-names></name><name><surname>Ito</surname> <given-names>S</given-names></name><name><surname>Utsumi</surname> <given-names>H</given-names></name><name><surname>Wakui</surname> <given-names>H</given-names></name><name><surname>Numata</surname> <given-names>T</given-names></name><name><surname>Kaneko</surname> <given-names>Y</given-names></name><name><surname>Mori</surname> <given-names>S</given-names></name><name><surname>Asano</surname> <given-names>H</given-names></name><name><surname>Yamashita</surname> <given-names>M</given-names></name><name><surname>Odaka</surname> <given-names>M</given-names></name><name><surname>Morikawa</surname> <given-names>T</given-names></name><name><surname>Nakayama</surname> <given-names>K</given-names></name><name><surname>Iwamoto</surname> <given-names>T</given-names></name><name><surname>Imai</surname> <given-names>H</given-names></name><name><surname>Kuwano</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Involvement of cigarette smoke-induced epithelial cell ferroptosis in COPD pathogenesis</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>3145</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-10991-7</pub-id><pub-id pub-id-type="pmid">31316058</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.62174.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Emoto</surname><given-names>Noriaki</given-names></name><role>Reviewing Editor</role><aff><institution>Kobe Pharmaceutical University</institution><country>Japan</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>This manuscript identified a role of iron-dependent cardiomyocyte death caused by autophagy-mediated ferritin degradation as a novel mechanism underlying chronic heart failure. The role of autophagy-dependent ferritin degradation was further strengthened by studies investigating nuclear receptor coactivator 4 (NCOA4), a cargo receptor that binds to the ferritin heavy chain. Its role was confirmed in an experimental model of chronic heart failure induced by transverse aortic constriction in mice carrying a cardiomyocyte-specific deletion of the NCOA4 gene.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Iron derived from autophagy-mediated ferritin degradation induces cardiomyocyte death and heart failure in mice&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by a Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>We would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, when editors judge that a submitted work as a whole belongs in <italic>eLife</italic> but that some conclusions require a modest amount of additional new data, as they do with your paper, we are asking that the manuscript be revised to either limit claims to those supported by data in hand, or to explicitly state that the relevant conclusions require additional supporting data.</p><p>Our expectation is that the authors will eventually carry out the additional experiments and report on how they affect the relevant conclusions either in a preprint on bioRxiv or medRxiv, or if appropriate, as a Research Advance in <italic>eLife</italic>, either of which would be linked to the original paper.</p><p>Summary:</p><p>The manuscript describes the role of ferritinophagy in pressure overload induced heart failure. It demonstrates that deletion of the ferritin chaperone NCOA4, which is involved in ferritinophagy, reduces the extent of cardiac remodelling following TAC. It also provides evidence implicating changes in intracellular iron pool as a key driving factor in cardiac remodelling. Ferroptosis, a form of iron-induced cell death, has already been shown to be important in DOX-induced cardiomyopathy (Fang et al., 2019). The present study provides a further example of the importance of iron-induced cell death in heart failure. Overall, the study is well-designed and well presented. There are a number of gaps and inconsistencies in the data, and these should be addressed in order to achieve a water-tight and cohesive manuscript.</p><p>Essential revisions:</p><p>1) Prolonged expression of the alpha-MHC-Cre transgene used to target the heart in the present study is well known to have off-target effects on heart function, independently of any floxed allele. The authors need to demonstrate that the differences in the response to TAC between NCOA4<sup>-/-</sup> and NCO4<sup>+/+</sup> animals are not due to the alpha-MHC-Cre transgene altering the heart's response to pressure overload stress. This should be achieved by comparing the outcome of TAC between wild type and those harbouring the alpha-MHC-Cre transgene.</p><p>2) Quantitation of ferritinophagy- Histology (Figure 3C) and western blot (Figure 3A) relating to ferritin levels appear to show different things. The Western blot appears to show that sham-operated NCOA4<sup>+/+</sup> and NCOA4<sup>-/-</sup> hearts have similar levels of ferritin, whereas FTH1 staining shows that sham-operated NCO4-/- hearts have higher levels of ferritin staining. Additionally, the Western blot shows that TAC did not affect the levels of ferritin in NCOA4<sup>-/-</sup> mice, whereas histology appears to show a reduction in ferritin staining by TAC. The authors need to provide better quality histological data, ensuring images are acquired in a manner that allows direct comparison between different treatment conditions.</p><p>3) Figure 4—figure supplement 1. The authors report that pressure overload reduced serum ferritin levels, and state that this suggests &quot;systemic iron deficiency&quot;. This statement is not supported by their data because serum iron and transferrin saturation are comparable across the board. The authors need to provide additional data to explain the reduction in ferritin levels, taking into account the fact that ferritin is both a marker of liver iron stores and an acute inflammatory protein. Measurement of liver iron levels and serum inflammatory markers (IL-6 and or CRP) would help in the interpretation of this result.</p><p>4) Figure 4. The authors state that their measurements of iron levels suggest &quot;free ferrous iron overload in TAC-operated <italic>Ncoa4</italic><sup>+/+</sup> hearts&quot;. At the same time, they report that the levels of FPN and TFR1 proteins are not altered in these hearts. These two findings contradict each other. Fpn and TfR1 are regulated by IRPs, which sense the levels of intracellular iron. If these increase, IRPs lose their RNA-binding function, thereby removing both the translational suppression on the Fpn transcript (resulting in increased FPN translation), and the stabilisation of the TfR1 transcript (resulting in reduced TfR1 expression). The authors need to provide more detailed analysis of IRP activity, using a more comprehensive panel of IRP-regulated genes and/or RNA binding assays. Crucially, they need to determine whether the IRP system is impaired in this setting or whether its activation is not sufficient to mitigate against changes in the size of the labile iron pool.</p><p>5) In Figure 4, while the authors characterized the glutathione and glutamine metabolism in pressure overload-induced cardiac hypertrophy, they did not examine the cystine-glutamate antiporter (System Xc-) that is a key regulator for cystine update in cell survival against ferroptosis. They should assess the expression of SLC7A11 in System Xc-, and cystine level in the cell. The expression level of glutamate also needs to be examined to evaluate the function of System Xc- in this setting. It might affect the level of L-glutamine, which is converted into glutamate by glutaminase.</p><p>6) In Figure 5, they used a ferroptosis inducer, erastin that inhibits the activity of System Xc-, leading to the depletion of GSH. To characterize the effects of NCOA4 deficiency in iron-dependent necrosis, they should use another ferroptosis inducer, RSL3 that inhibits GPX4 directly.</p><p>7) Figure 6. The data presented here are interesting but do not directly support the results seen in NCOA4<sup>-/-</sup> mice. To integrate these results into the rest of the study and to support their statements on the role of iron-dependent cell death downstream of NCOA4, the authors need to determine whether ferrostatin provides additional protection from cardiac remodelling in NCOA4<sup>-/-</sup> mice. If it does, then the protective effect of ferrostatin cannot be attributed to mitigating he effects of ferritinophagy.</p><p>8) While they discussed possible mechanisms of isoproterenol induced iron-dependent necrosis, it is unclear what is a potential mechanism for that. They need to discuss it more with additional data or references. For example, Isoproterenol or erastin-induced ferroptosis mechanism had been well known such as NRF2/HO-1pathway and VDACs-induced mitochondrial dysfunction (as reviewed by Li et al., 2020). Does NCO4 have association with these pathways in ferroptosis-induced cardiomyocytes death and heart failure?</p><p>9) Tang et al. (Free Radic Biol Med 2019 Apr; 134: 445-457) mentioned in their study that NCOA4 has association with mitochondria iron-overload in cardiomyocyte hypertrophy pathophysiology. Please discuss on the possibility that NCO4 has association with these pathways in ferroptosis-induced cardiomyocytes death and heart failure.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.62174.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) Prolonged expression of the alpha-MHC-Cre transgene used to target the heart in the present study is well known to have off-target effects on heart function, independently of any floxed allele. The authors need to demonstrate that the differences in the response to TAC between NCOA4<sup>-/-</sup> and NCO4<sup>+/+</sup> animals are not due to the alpha-MHC-Cre transgene altering the heart's response to pressure overload stress. This should be achieved by comparing the outcome of TAC between wild type and those harbouring the alpha-MHC-Cre transgene.</p></disp-quote><p>I agree with your comments that prolonged expression of the alpha-MHC-Cre transgene in some transgenic lines is known to have off-target effects on heart function as previously reported (J Card Fail. 2006, 12:392-398). Our alpha-MHC-Cre (Myh6-Cre) transgenic mice have been generated in our laboratory (J Clin Invest 2004, 114:937-843) and used for a series of our and others’ studies. In this study, please note that control <italic>Ncoa4</italic><sup>flox/flox</sup>;Myh6-Cre<sup>–</sup> mice developed more severe chamber dilation and cardiac dysfunction than <italic>Ncoa4</italic><sup>flox/flox</sup>;Myh6-Cre<sup>+</sup> mice. Thus, the reported detrimental effect of prolonged expression of the transgene on cardiac function cannot explain our data showing ablation of <italic>Ncoa4</italic> induced cardioprotective effects. However, in the revised manuscript, we performed TAC operation on Myh6-Cre<sup>+</sup> and Myh6-Cre<sup>–</sup> mice. There were no significant differences in echocardiographic parameters between the two groups 4 weeks after TAC. Thus, the overexpression of Cre recombinase in the heart has no effect on pressure overload-induced cardiac remodeling. We showed the data in Figure 1—figure supplement 4 and mentioned the data in the Results section.</p><disp-quote content-type="editor-comment"><p>2) Quantitation of ferritinophagy- Histology (Figure 3C) and western blot (Figure 3A) relating to ferritin levels appear to show different things. The Western blot appears to show that sham-operated NCOA4<sup>+/+</sup> and NCOA4<sup>-/-</sup> hearts have similar levels of ferritin, whereas FTH1 staining shows that sham-operated NCO4<sup>-/-</sup> hearts have higher levels of ferritin staining. Additionally, the Western blot shows that TAC did not affect the levels of ferritin in NCOA4<sup>-/-</sup> mice, whereas histology appears to show a reduction in ferritin staining by TAC. The authors need to provide better quality histological data, ensuring images are acquired in a manner that allows direct comparison between different treatment conditions.</p></disp-quote><p>Thank you very much for your comments. We have provided better quality of histological data (Figure 3C).</p><disp-quote content-type="editor-comment"><p>3) Figure 4—figure supplement 1. The authors report that pressure overload reduced serum ferritin levels, and state that this suggests &quot;systemic iron deficiency&quot;. This statement is not supported by their data because serum iron and transferrin saturation are comparable across the board. The authors need to provide additional data to explain the reduction in ferritin levels, taking into account the fact that ferritin is both a marker of liver iron stores and an acute inflammatory protein. Measurement of liver iron levels and serum inflammatory markers (IL-6 and or CRP) would help in the interpretation of this result.</p></disp-quote><p>Thank you very much for your comments. In the revised manuscript, we showed the liver iron and serum IL-6 levels in Figure 4—figure supplement 2. TAC decreased the level of total non-heme iron in both <italic>Ncoa4<sup>-/-</sup></italic> and <italic>Ncoa4<sup>+/+</sup></italic> livers, and there was no significant difference in the level between <italic>Ncoa4<sup>-/-</sup></italic> and <italic>Ncoa4<sup>+/+</sup></italic> livers. TAC increased the serum IL-6 level in <italic>Ncoa4<sup>-/-</sup></italic> and <italic>Ncoa4<sup>+/+</sup></italic> mice, which was higher in <italic>Ncoa4<sup>+/+</sup></italic> than that in <italic>Ncoa4<sup>-/-</sup></italic> mice. It has been reported that serum IL-6 level is upregulated in heart failure. Taking into account the fact that ferritin is both a marker of liver iron stores and an acute inflammatory protein as you indicated, the reduced level of serum ferritin in pressure overloaded hearts is due to a reduction in liver iron stores. We deleted the description “systemic iron deficiency” in the Results and Discussion sections and mentioned the data and interpretation in the Results section.</p><disp-quote content-type="editor-comment"><p>4) Figure 4. The authors state that their measurements of iron levels suggest &quot;free ferrous iron overload in TAC-operated Ncoa4<sup>+/+</sup> hearts&quot;. At the same time, they report that the levels of FPN and TFR1 proteins are not altered in these hearts. These two findings contradict each other. Fpn and TfR1 are regulated by IRPs, which sense the levels of intracellular iron. If these increase, IRPs lose their RNA-binding function, thereby removing both the translational suppression on the Fpn transcript (resulting in increased FPN translation), and the stabilisation of the TfR1 transcript (resulting in reduced TfR1 expression). The authors need to provide more detailed analysis of IRP activity, using a more comprehensive panel of IRP-regulated genes and/or RNA binding assays. Crucially, they need to determine whether the IRP system is impaired in this setting or whether its activation is not sufficient to mitigate against changes in the size of the labile iron pool.</p></disp-quote><p>We have analyzed of IRP activity by examining mRNA levels of IRP-regulated genes such as <italic>Tfrc</italic>, <italic>Slc11a2</italic>, <italic>Cdc14a</italic>, and <italic>Cdc42bpa</italic> (Figure 4—figure supplement 3B) and RNA binding activity for ferroportin 1 (SLC40A1) (Figure 4—figure supplement 3C). There were no significant differences in all parameters between TAC-operated <italic>Ncoa4<sup>-/-</sup></italic> and <italic>Ncoa4<sup>+/+</sup></italic> mice. Thus, the data indicates that the IRP system is impaired in this setting. We mentioned this in the Results section.</p><disp-quote content-type="editor-comment"><p>5) In Figure 4, while the authors characterized the glutathione and glutamine metabolism in pressure overload-induced cardiac hypertrophy, they did not examine the cystine-glutamate antiporter (System Xc-) that is a key regulator for cystine update in cell survival against ferroptosis. They should assess the expression of SLC7A11 in System Xc-, and cystine level in the cell. The expression level of glutamate also needs to be examined to evaluate the function of System Xc- in this setting. It might affect the level of L-glutamine, which is converted into glutamate by glutaminase.</p></disp-quote><p>We examined the expression level of <italic>Slc7a11</italic> mRNA. There was no significant difference between any groups (Figure 4—figure supplement 5A). Cardiac cystine level showed no difference between TAC-operated <italic>Ncoa4<sup>-/-</sup></italic> and <italic>Ncoa4<sup>+/+</sup></italic> mice (Figure 4—figure supplement 5B). The level of glutamate in TAC-operated <italic>Ncoa4<sup>+/+</sup></italic> hearts was lower than that in sham-operated <italic>Ncoa4<sup>+/+</sup></italic> or TAC-operated <italic>Ncoa4<sup>-/-</sup></italic> hearts (Figure 4—figure supplement 5C). We described the data in the Results section and the Discussion section.</p><disp-quote content-type="editor-comment"><p>6) In Figure 5, they used a ferroptosis inducer, erastin that inhibits the activity of System Xc-, leading to the depletion of GSH. To characterize the effects of NCOA4 deficiency in iron-dependent necrosis, they should use another ferroptosis inducer, RSL3 that inhibits GPX4 directly.</p></disp-quote><p>In the revised manuscript, we examined the effect of RSL3 on cardiomyocyte death. RSL3 induced cardiomyocyte death, which was attenuated by <italic>Ncoa4</italic> ablation or ferrostatin-1 treatment as erastin (Figure 5—figure supplement 2). We mentioned the data in the Results section.</p><disp-quote content-type="editor-comment"><p>7) Figure 6. The data presented here are interesting but do not directly support the results seen in NCOA4<sup>-/-</sup> mice. To integrate these results into the rest of the study and to support their statements on the role of iron-dependent cell death downstream of NCOA4, the authors need to determine whether ferrostatin provides additional protection from cardiac remodelling in NCOA4<sup>-/-</sup> mice. If it does, then the protective effect of ferrostatin cannot be attributed to mitigating he effects of ferritinophagy.</p></disp-quote><p>In the revised manuscript, we examined the effect of ferrostatin-1 on pressure overload-induced cardiac remodeling in <italic>Ncoa4<sup>-/-</sup></italic> mice. Four weeks after TAC, there were no significant differences in echocardiographic and physiological parameters between saline- and ferrostatin-1-treated mice (Figure 6—figure supplement 2). Thus, this result indicates that iron-dependent cell death is downstream of NCOA4-mediated pathway. We mentioned these in the Results and Discussion sections.</p><disp-quote content-type="editor-comment"><p>8) While they discussed possible mechanisms of isoproterenol induced iron-dependent necrosis, it is unclear what is a potential mechanism for that. They need to discuss it more with additional data or references. For example, Isoproterenol or erastin-induced ferroptosis mechanism had been well known such as NRF2/HO-1pathway and VDACs-induced mitochondrial dysfunction (as reviewed by Li et al., 2020). Does NCO4 have association with these pathways in ferroptosis-induced cardiomyocytes death and heart failure?</p></disp-quote><p>In the revised manuscript, we examined the effect of isoproterenol on ferritinophagy. Isoproterenol decreased the FTH1 protein level in isolated cardiomyocytes in an NCOA4 dependent manner, indicating that isoproterenol induces cardiomyocyte death by activation of NCOA4-mediated ferritinophagy (Figure 5E). We mentioned these in the Results and Discussion sections.</p><p>We added the sentence “It is possible that NCOA4 may associate with NRF2/HO-1 and VDACs-induced mitochondrial dysfunction pathways in ferroptosis-induced cardiomyocytes death and heart failure” in the Discussion section.</p><disp-quote content-type="editor-comment"><p>9) Tang et al. (Free Radic Biol Med 2019 Apr; 134: 445-457) mentioned in their study that NCOA4 has association with mitochondria iron-overload in cardiomyocyte hypertrophy pathophysiology. Please discuss on the possibility that NCO4 has association with these pathways in ferroptosis-induced cardiomyocytes death and heart failure.</p></disp-quote><p>Thank you very much. In the revised manuscript, we mentioned mitochondria iron-overload as a possible mechanism in cardiomyocyte hypertrophy pathophysiology in the Discussion section. Although NCOA4-mediated ferritin degradation contributes to maintain mitochondrial function through iron supply, excessive ferritinophagy may induce cardiomyocyte hypertrophy and cell death. We need further study to elucidate the mechanism for NCOA4-medicated cardiomyocyte death and heart failure.</p></body></sub-article></article>